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 Coronaviruses (CoVs) are common human and animal pathogens causing a 
range of organ pathologies including respiratory, gastrointestinal, and brain diseases.  
In humans, four endemic CoV species together account for one third of mild respiratory 
infections worldwide. More severe and frequently fatal respiratory pathologies are 
caused by recent CoV outbreaks that resulted from occasional zoonotic spillover from 
animal CoV reservoirs. Within the past 18 years, we humans have experienced three of 
such outbreaks. The causative agents of these outbreaks are: SARS-CoV in 2002, 
MERS-CoV in 2012, and SARS-CoV-2 in 2019, with the outbreaks caused by the latter 
two still ongoing. These CoVs collectively have demonstrated the spread of CoVs in 
human populations, as well as highlighted the threat CoVs impose on global health as 
an emerging viral pathogen. Any chance of relieving CoV’s threat on human populations 
would rely heavily on our understanding of the mechanistic requirements for CoV 
tropism. The major determinant for CoV tropism happens during viral entry. CoVs have 
evolved to use a single viral protein for entry: spike (S). The S protein binds viruses to 
host cell receptors and catalyzes virus-cell membrane fusion, an entry requirement for 
all enveloped viruses. Uniquely, CoV S proteins contain at least two receptor binding 
domains, a domain A that generally engages host sialic acids, and a domain B that 
recognizes host transmembrane proteins.  A putative advantage of this bivalent binding 
is elevated CoV zoonotic potential, for each binding domain can, theoretically, 




identify roles for each receptor for the S proteins of two beta-coronaviruses, the 
prototypic MHV-CoV strain JHM and human MERS-CoV. We focused on three distinct 
stages of the CoV life cycle: (1) CoV particle-cell binding; (2) CoV particle-cell entry; (3) 
CoV cell-to-cell spread, where the infection passes directly from an infected cell to a 
neighboring healthy cell via cell-cell fusion, or syncytia formation. For MHV-JHM S 
protein, we identified its interaction with host sialic acids, using a virus-like particle 
(VLP) system. The interaction with sialic acids, and not with the protein receptor, is 
responsible for the majority of the particle binding mediated by the S protein. 
Additionally, the S-sialic acid interaction assists in JHM-CoV entry into various target 
cells, as well as the subsequent cell-to-cell spread, both in the presence and absence of 
the protein receptor. For the S protein of MERS-CoV, we first found that viral particles 
minimally require S, protein receptor, and protease for fusion. Additionally, similar to 
JHM, MERS S-sialic acid interaction is sufficient for cell-cell fusion. Lastly, we identified 
single-nucleotide changes in both S protein-sialic acid binding S domain As that 
conferred elevated cell-binding and cell-cell fusion capabilities. Overall, these findings 
reveal roles for sialic acids in virus-cell binding, viral S protein-directed cell-cell fusion, 
and resultant spread of CoV infections. This study highlights distinctive CoV receptor 
binding domain activities in the infection process and raise the possibility that the lectin-
like properties of many CoVs are responsible for facile CoV zoonotic transmission and 





REVIEW OF LITERATURE 
Coronaviruses 
Coronaviruses (CoVs) are positive-sense, single-stranded RNA (ssRNA) viruses 
that contain the largest genome of all RNA viruses, which ranges from 24 to 32 
kilobases (kb). The 5’ two-thirds of the CoV genome encodes the various non-structural 
proteins, and is expressed as a polyprotein. The 3’ one third of the CoV genome 
encodes the structural and accessory proteins, whose expressions result from the 
generation of viral subgenomic RNAs (Figure 1A). CoVs are phylogenetically 
categorized under the order Nidovirales and are subcategorized into four groups (alpha-
, beta-, gamma-, and delta-).  
CoVs are enveloped viruses, meaning the mature virion consists of an outer-
most layer made up of a lipid bilayer derived from the host membrane, enriched with 
transmembrane viral proteins. Indeed, three out of four CoV major structural proteins 
and sometimes a non-major structural protein can be found on the CoV envelope. 
These are the spike (S) protein, membrane (M) protein, envelope (E) protein, and 
hemagglutinin esterase (HE). The nucleocapsid (N) proteins associates with the CoV 
genome and, through its interactions with the self-assembled M proteins, resides inside 
the viral particle (1–6). Together with the CoV genomic RNA, these structural proteins 
form a complete, infectious virion (Figure 1B).
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Figure 1. Murine Hepatitis Virus (MHV) Genomic and Virion Structure. (A) CoV 
genomic (top) and subgenomic (bottom) structures, using murine hepatitis virus (MHV) 
as an example. CoV subgenomic RNAs are generated by joining of the 5’ leader (red 
box) sequence to various downstream sites. CoV non-structural genes consists of the 5’ 
two-thirds of the RNA genome, whereas structural genes are located within the 3’ one-
third. During viral replication, non-structural genes are expressed as polyproteins, while 
structural genes are expressed by each subgenomic RNAs. Accessory genes are 
numbered. (B) Schematic for CoV virion composition. Viral structural proteins S, E, M, 
and sometimes HE, are incorporated in the viral envelope. N proteins associate with the 
genomic RNA (gRNA) and are together incorporated into the virion interior. The color 
codes are consistent between panel A and B. 
 
CoVs are highly adaptive, in part due to their error-prone RNA-dependent RNA 
polymerase (RdRp), whose substitution rate has been averaged to ~10-4 per year per 
site, with even higher rates for certain hypervariable regions (i.e. S protein), at 0.6 x 10-2 
per site per year (7, 8). Another contributor for CoV adaptability is the RNA 
recombination during viral replication, via the process of RdRp template-switching (9–
12). Together with a large genome size, which tolerates higher genome variations, and 
the generation of subgenomic RNAs during viral replication, which elevates the rate of 
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homologous recombination between different viral lineages, CoVs are capable of 
quickly adapting to a wide range of biological niches. 
Coronaviruses Threatens Global Health 
CoVs were initially isolated in 1930s from chickens (13), and 1940s from swine 
(14) and mice (15). Human CoVs were first identified in 1967 from tissue samples of the 
upper respiratory track (16). To this day, there are four CoVs that cause mild respiratory 
track infections in humans, with occasional fatalities with immunocompromised 
individuals. These are human coronavirus 229E (229E-CoV (16)), human coronavirus 
OC43 (OC43-CoV (16)), human coronavirus NL63 (NL63-CoV (17, 18)), and human 
coronavirus HKU1 (HKU1-CoV (19)). They together account for about one-third of 
common colds worldwide (20, 21), highlighting the spread of CoVs in human 
populations. 
CoVs responsible for more recent human outbreaks, however, cause severe, 
often fatal acute respiratory syndromes (22–29). In November 2002, a CoV epidemic 
started in the Guangdong province of southern China. The virus was moderately apt at 
human-human transmission, and had spread to 26 countries and infected over 8000 
individuals, with 15% fatality (28). This epidemic was fortunately contained and 
subsequently eliminated via effective epidemiologic approaches (30). The CoV in 
question was later identified and designated Severe Acute Respiratory Syndrome 
(SARS)-CoV. This initial demonstration of the extent to which CoVs can threaten global 
health was echoed only a decade later in the Middle East. In 2012, another CoV 
epidemic broke out in and around Saudi Arabia, causing lethal pneumonia (26, 31). 
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Since then, this epidemic has mainly been contained in the Middle East, around the 
Arabian Peninsula, with Saudi Arabia containing the most cases. Since the onset of the 
outbreak in 2012, however, the virus has been occasionally exported to other countries 
via infected individuals, sometimes causing clusters of secondary outbreaks, the largest 
of which happening in South Korea in 2015. The causative agent for this epidemic was 
identified and designated Middle-East Respiratory Syndrome (MERS)-CoV, and as of 
this writing, the epidemic is still ongoing. As of November 2019, MERS-CoV has caused 
a total of 2494 laboratory-confirmed cases, with 34% fatality (32). Currently (as of Feb. 
16, 2020), a pneumonia outbreak originated from Wuhan, China, in ongoing, infecting 
over 71,000 individuals, over 11,000 in serious or critical conditions, and over 1,700 
fatalities. This outbreak is identified to be caused by a novel SARS-like CoV (2019-
nCoV, or SARS-CoV-2), which has been sequence-identified in a large number of 
patients (33). Together with SARS-CoV and MERS-CoV, these recent human outbreaks 
demonstrate the threat CoVs impose on global health as an emerging viral pathogen. 
Coronaviruses are Zoonotic Pathogens 
CoVs primarily infect the respiratory and gastrointestinal tract and cause endemic 
infections in a wide range of mammalian and avian species. For any individual CoV, it 
mostly appears to be restricted to a narrow host range, species, or even tissue. This is 
likely because all current viruses are results of highly-specific adaptations, and therefore 
do not actively display their zoonotic potentials, or the ability to jump from one animal 
species to another. However, viral genome sequencing and subsequent phylogenetic 
analyses reveal that CoVs have crossed the zoonotic barrier frequently (34, 35). 
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In fact, all human CoVs share a common ancestor with bat CoVs, suggesting 
that, throughout history, bat CoVs were transmitted to humans. These transmissions 
could be direct, or indirectly through an intermediate animal species. For example, 
ancestral 229E-CoV likely resided in bats up until around 200 years ago, when it 
transmitted and became endemic in an intermediate host, possibly camelids, before it 
eventually spread to humans (36). OC43-CoV, on the other hand, is the result of a 
recent (~1890s) cross-species transmission event of bovine (B-) CoV, which has been 
endemic in cows (37, 38). Similarly, ancestors of NL63-CoV and HKU1-CoV both have 
successfully breached the species barrier and are maintained in the human populations 
worldwide (21). These four human CoVs, which cause mild respiratory tract infections 
and are distributed in human populations globally seemingly without animal reservoirs, 
are considered well-adapted to humans. 
On the other hand, those CoVs that have only recently entered into human 
populations tend to cause more severe or fatal pneumonia, and are considered not-well-
adapted. Such CoVs are likely maintained in zoonotic reservoirs, and via intermediate 
host species, occasionally spillover into the human population. In the past 18 years, the 
world witnessed three such zoonotic events. For example, epidemiology data had 
traced the 2002 SARS-CoV outbreak to the masked palm civets (Paguma larvata) from 
local live animal markets (39–41). Interestingly, while the civets in the markets were 
infected, wild civets were largely SARS-CoV-negative (40). This suggests that the virus 
was not endemic in the masked palm civets, who are merely the intermediate host, and 
not the reservoir, for the human transmission. Conversely, it was identified that SARS-
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CoV and a number of SARS-like CoVs were present in the region’s Chinese horseshoe 
bats (Rhinolophidae family), suggesting their role as the animal reservoir for the virus 
(12, 42, 43). The current zoonosis model for SARS-CoV describes a transmission path 
from bats to civets, and then civets to human. 
A similar zoonotic trajectory was proposed for MERS-CoV. Immediately after the 
onset of the MERS outbreak in 2012 and the identification of the virus, dromedary 
camels were found to contain neutralizing antibodies against MERS-CoV. This is the 
case for both camels in the outbreak zone of the Arabian Peninsula and camels that 
had originated there but had since been exported around Africa (44, 45). Unlike the 
case with SARS-CoV and civets, this finding suggests that dromedary camels are likely 
the animal reservoir. Additionally, live MERS-CoV can be readily isolated from the nasal 
swabs of these camels (46–48), suggesting that they are the likely source of the viral 
infection, possibly via contaminated body fluids of the animal’s respiratory tract. The 
reason the viral outbreak happened in the Middle East and not in Africa is potentially 
due to the differences in the regional concentrations of camels and their proximity to 
large human populations. In support of the claim that camels are the animal reservoirs 
for MERS-CoV, a recent survey of camel CoVs in Saudi Arabia revealed that multiple 
lineages of MERS-CoVs co-circulate within these animals. Evidently, these co-
circulating MERS-CoV strains had recombined and resulted in a MERS-CoV strain that 
had dominated the camel population by 2014. Most intriguingly, the same recombinant 
MERS-CoV was responsible for the viral outbreaks in the year of 2015 (49). 
Interestingly, camelids might not be the only animal in the outbreak zone that can carry 
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the virus. While MERS-CoV has yet to be found in bats to date, viral genome fragments 
identical to MERS-CoV have been identified in bats around the Arabian Peninsula 
(Taphozous perforatus (50)) and South Africa (Neoromicia zuluensis (51)). Additionally, 
CoVs that display the closest phylogenetic relationship with MERS-CoV are bat-CoVs 
HKU4 (52) and HKU5 (53). Taken together, these findings support a MERS-CoV 
zoonosis model that is analogous to SARS-CoV, where the ancestral MERS-CoV 
spread from bats to camelids, and then camelids to human. 
As of this writing, more information on the SARS-CoV-2 outbreak is being 
updated daily. While there has not been conclusive analyses on the source(s) and 
reservoir(s) of the virus, several patients were associated with a local seafood market 
(33). Additionally, the SARS-CoV-2 genome is most closely related to one SARS-like 
CoV in Bats (54). The specific epidemiological relationship between SARS-CoV-2, the 
seafood market, and bats is an area of great importance. Taken together, human CoVs, 
including four endemic stains and three outbreak-causing animal-spillovers, have 
demonstrated the level of viral prevalence, facile zoonotic transmission, and potential to 
cause severe respiratory disease. This brings urgency to research aimed at discovering 
CoV infection mechanisms, and specifically, CoV features that prime zoonosis. 
Bats are the Most Prominent CoV Reservoirs 
All human CoVs can be genetically traced back to bats, which has been 
estimated to be the largest reservoir of alpha- and beta-CoVs (34). Indeed, out of the 
numerous animal species that have been surveyed, bats have risen out to be one of the 
most abundant source for novel viral sequences (55). There may be several key 
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characteristics that contribute to this understanding. First of all, bats are among the 
oldest and most diverse mammals. Being of the order Chiroptera, bats comprise about 
20% of all classified mammalian diversity, with over 1,200 species (56). This diversity 
offers encompassing biological niches for viral adaptation. Secondly, bat ecology 
ranges from isolated individuals to mega-colonies occupying diverse niches that can 
span thousands of miles, greatly enabling viral spread and co-circulation. Third, for 
reasons unclear, despite being identified with such a diverse assortment of viruses, bats 
rarely manifest disease. One attractive explanation links this phenomenon to the ability 
of flight (57). Being the only flying mammal, bats produce a large amount of reactive 
oxygen species (ROS), and hence have evolved to limit oxidative stress (58), which 
could, inadvertently, limit viral replication and pathogenesis (59). Additionally, several 
bat species lack or repress components of the inflammasome and natural killer 
pathways, which could limit disease and post-infection damage (58, 60). Furthermore, 
unlike most other mammals, bat interferon (IFN) is less responsive to canonical 
inflammatory signals (61), but instead is constitutively expressed at high levels, which 
could modulate disease but maintain low-level viral infections (62). Lastly, most bat-
CoVs were isolated from bat gut, a very different immunological environment than the 
respiratory tract, which could be more tolerant for viral maintenance. These factors likely 
work in unisons to shape bats into an organism highly suitable for viral adaptation and 
evolution. 
In addition to the high tolerance to CoV presence, the immunological 
environment in bats may also diversify viral quasi-species gene pools. Flight-induced 
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ROS may act as a mutagen for CoVs by overwhelming CoV proofreading repair, or 
altering RNA-dependent RNA-polymerase (RdRp) fidelity (63). Increases in the quasi-
species pool size potentiate viral adaptations into new hosts. Furthermore, the 
constitutive, instead of inducible, expression of IFN in bats may select for CoVs that 
have adapted for enhanced resistance to innate immunity (62). Viral adaptions such as 
these may encounter little resistance, due to the bat’s lack of key inflammatory 
mediators (60, 61). This may result in some viral variants with a replication advantage 
when they infect a new host, possibly associated with massive and pathogenic 
inflammatory responses. These phenotypes have been observed with both SARS-CoV 
and MERS-CoV infections in humans (64–66). Taking together, bats host CoVs and 
may enhance CoV zoonotic potential by enriching viral diversity, potentially selecting for 
innate immunity-adaptive variants. 
Enveloped Virus Entry Requires Membrane Fusion 
The viral genome of enveloped viruses, including CoVs, are encased in a lipid 
bilayer derived from the infected host. Therefore, to deliver the viral genome into the 
target cell cytoplasm to establish infection, the virus and target cell membranes need to 
fuse together (Figure 2A). Hence, viral fusion follows the underlining principles of 
membrane fusion. 
Biological membranes are consist of amphipathic phospholipids, each of which 
are composed of a hydrophilic head group and two hydrophobic tails. In aqueous (i.e. 
H2O) environments, phospholipids aggregate via the cis-hydrophilic and cis-
hydrophobic interactions between the head groups and tails, respectively. The resulting 
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macromolecular structures position the hydrophilic head groups against water 
molecules, while shielding the hydrophobic tails. The most stable of these structures is 
a membrane vesicle, compartmentalized by a phospholipid bilayer. Due to this 
architecture, most hydrophilic molecules cannot penetrate the membrane bilayer. 
Therefore, one approach to achieve the delivery or exchange of internal molecules of 
two particular vesicles, e.g. an enveloped virus and its target cell, is the melding of the 
lipid bilayers, or membrane fusion. 
The current model describes that membrane fusion is completed in several steps (67). 
First, the two membranes in question have to come into close proximity, close enough 
that the transfer of a few phospholipids from one membrane to another would not 
compromise the bilayer architecture. This is facilitated by the “positive” curvatures 
(curves extending toward the target membrane), such as the membrane curvature on 
the virus against the membrane on the target cell (68). At this proximity, the 
phospholipids on the proximal leaflets of the two membranes are capable of interacting 
and merging, forming a continuous lipid layer, while the distal leaflets remain distinct 
(69, 70). This is the state of hemifusion (Figure 2A), where the exchange of membrane 
lipids, but not lumen contents, is permitted. If the fusion process does not stall on 
hemifusion, eventually the distal lipid leaflets will merge, and form a fusion pore (Figure 
2A). At this stage, the two compartments are joined and their lumen contents are mixed. 
For enveloped viruses, fusion pore formation enables its viral genome to enter the host 
cytoplasm and hence concludes the viral entry process. 
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Figure 2. The Progression of Membrane Fusion. (A) Membrane fusion takes place in 
several steps. First, opposing membranes (made up of lipids with brown a head group 
and black hydrophobic tails) are brought into close proximity, likely aided by positive 
membrane curvatures away from compartment lumens (orange and blue).  Then, outer 
leaflets of the membrane merge, forming a hemifusion intermediate.  Finally, distal 
leaflets merge to complete fusion pore formation, allowing for the mixing of 
compartment lumens (now green). (B) During viral entry, the viral envelope is localized 
to the host membrane by the interactions between the viral glycoprotein (for CoVs, 
spike) and the host receptor. Upon exposure to subsequent host triggering factors (for 
CoVs, cleavage(s) of spike by host proteases), the viral glycoprotein goes through 
extensive conformational changes, resulting in its extension and insertion into the target 
cell membrane, physically bridging the two membranes together. Then, the glycoprotein 
completes its conformational changes by folding back onto itself, while bringing the two 
membranes into close proximity by creating positive membrane curvatures (see panel 
A). If successful, the process will proceed to hemifusion and fusion pore formation, 
concluding viral entry. 
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While a fused membrane is at a lower free energy state than two unfused ones, 
meaning membrane fusion is thermodynamically favorable, the energy barrier for 
membrane fusion is high, making it kinetically unfavorable. As the result, biological 
membrane fusions evolved fusion catalysts that lower this kinetic barrier (67, 71–73), 
resulting in highly-regulated fusion processes. The most well-studied membrane fusion 
catalysts are the viral glycoproteins on enveloped viruses. Viral glycoproteins are 
transmembrane proteins synthesized in the endoplasmic reticulum (ER). These proteins 
are folded in ways such that intramolecular energy is stored and maintained (71) either 
through internal interactions (74) or by the actions of associated viral proteins (75). 
When the virus becomes associated with the target cell membrane prior to viral entry, in 
the presence of appropriate host triggering factors, the viral glycoprotein will go through 
a dramatic conformational unfolding and refolding, exhausting the stored energy in an 
attempt to pull the viral and target cell membrane together to enable fusion (74, 76, 77). 
Additionally, because the structural transition endpoint into which the viral glycoprotein 
refolds is highly thermodynamically favorable, the protein will be “locked” in that 
endpoint conformation and becomes inactive (78). In other words, a viral glycoprotein 
generally can go through the conformational changes that are required for membrane 
fusion only once. It is therefore crucial for these glycoproteins to remain inactive on the 
virion until the virus reaches the environment that is ideal for membrane fusion and 
infection. To acquire optimal entry efficiency, enveloped viruses have evolved their 
glycoproteins to recognize specific cellular and environmental factors as fusion triggers. 
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Several host factors can be recognized by enveloped viruses as fusion triggers. 
These include host cell receptors, local proton concentrations, and proteases. Some 
viruses only require a single trigger for fusion. For example, influenza A virus (IAV), 
West-Nile virus (WNV), and vesicular stomatitis virus (VSV) glycoproteins are triggered 
by elevated local proton concentration, a feature in the host endosome (74, 79, 80). 
Other viruses may require multiple triggers for fusion. Human immunodeficiency virus 
type 1 (HIV-1) glycoprotein, via sequential engagements with its receptor and 
coreceptors, undergo dramatic conformational changes to facilitate fusion (81–84). 
Ebola virus (EBOV) glycoprotein requires endosomal protease cleavage before it can 
bind to its endosomal receptor, and fusion is only triggered after a subsequent, 
uncharacterized step (85–90). 
Viral glycoproteins are structurally categorized into three classes (71). While the 
structure and triggering mechanisms for these viral glycoproteins can vary greatly, their 
fusion processes, once triggered, share many common features. First, in their pre-
fusion, ready-to-be-triggered conformation, viral glycoproteins bury a short stretch of 
hydrophobic residues called a fusion peptide (91–93). Upon triggering, the protein 
initiates dramatic structural transitions, which unveil the fusion peptide and extend it 
towards the target cell membrane. If the target cell membrane is within range, the fusion 
peptide will insert into this membrane and, due to its hydrophobicity, be anchored 
among the hydrophobic tails of the phospholipids. At this stage, the viral glycoprotein 
assumes a conformation known as the extended fusion intermediate. This conformation 
is putatively short-lived, because to complete the structural transition the glycoprotein 
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requires its transmembrane domain to coincide with the fusion peptide (94–96). 
Therefore, the glycoprotein then refolds onto itself. Since the transmembrane domain is 
on the viral envelope and the fusion peptide is in the target cell membrane, this refolding 
pulls the two membranes into close proximity. Then, the outer leaflets of the lipid 
bilayers meld to establish hemifusion (69), and if this progresses, the inner leaflets also 
meld to form a fusion pore (97). Due to the high energy barrier for membrane fusion, it 
is likely that most if not all enveloped viruses require the simultaneous refolding of 
multiple glycoprotein complexes to establish the fusion pore (74, 79, 80). Once the 
fusion pore is formed and maintained, the viral genome can invade the host cell 
cytoplasm, and hence concludes the process of viral entry. 
Coronavirus Entry 
As an enveloped virus, CoV entry requires membrane fusion. The mechanism by 
which CoVs enter host cells may explain, in part, the remarkable expansion of these 
viruses into new hosts, including humans. For any particular virus to achieve cross-
species transmission, it is generally accepted that four criteria need to be met (98). 
First, to achieve a specific cellular tropism, the target cell need to be susceptible, in 
other words, expressing the appropriate receptor needed for entry. Second, the target 
cell needs to be permissive, that is to say, allowing the virus to replicate so as to 
complete its life cycle. Third, these susceptible and permissive cells need to be 
accessible, in a biologically meaningful way, to the virus. Lastly, the innate immune 
response of a particular host must tolerate the early rounds of viral growth. For CoVs, 
while their non-structural gene products govern viral replication and the accessory 
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proteins assist in host tropism and adaptation (Figure 1A), the CoV entry process (i.e. 
host susceptibility) appears to be the main determinant for the success of initial cross-
species infection events. 
CoVs have evolved to use a single viral protein for entry: the spike (S) protein 
(Figure 2B). The S proteins adhere viruses to host-cell receptors, and they 
subsequently function as catalysts of virus-cell membrane fusion (99, 100). S protein is 
a class I viral fusogen (101), sharing the category with IAV hemagglunin (HA), HIV 
gp160, and EBOV GP (71). Like other class I fusogens, CoV S folds into a metastable 
pre-fusion conformation in a homotrimeric structure (Figure 3). S proteins are large N-
glycosylated glycoproteins, and among different CoV species it can vary greatly in size, 
ranging from 1300 to 1600 amino acid residues, and 160 to 220 kDa (99, 100). Native S 
proteins are trimeric, and form 18-23 nm long, club-shaped spike protrusions out of the 
membrane. This can be clearly observed under the electron microscope (EM) as 
bulbous surface projections on the viral envelope (102). CoV S is a type I 
transmembrane protein: a large N-terminus ectodomain, a single-pass transmembrane 
domain, and a short C-terminus tail. Functionally, the S protein can be divided into two 
distinct subunits: A globular membrane-distal S1 subunit (Figure 3, right) that is involved 
in host attachment and receptor recognition, and the membrane-associated S2 subunit 
(Figure 3, right) that facilitates membrane fusion. This conceptual separation of S1 and 
S2 is a reflection of the natural arrangement. All identified CoV S proteins contain a 
cleavage site between S1 and S2, which is recognized by host proteases. 
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Figure 3. Coronavirus Spike Protein. The CoV virion structure is depicted as shown in 
Figure 1 (top). One single S protein functional unit (red box) is a trimer of S monomers. 
Each S monomer is depicted in surface representation and colored green, cyan, or 
magenta. S trimers are shown both from profile (center) and top-down (left) vantage 
points. The S trimer is formed by S monomers interlacing onto each other. The magenta 
monomer is re-depicted as cartoons of secondary structures (right). The receptor-
engaging S1 subunit is colored yellow, and the membrane-fusing S2 subunit is colored 
gray. The S protein of MHV (PDB: 3JCL) is used as an example for generalizing CoV S 
structures. 
 
The S proteins cannot facilitate membrane fusion with S1 covalently linked to S2, and 
only after the liberation of the two domains that is the S1/S2 cleavage, either during 
virion assembly or viral entry, can viral fusion be initiated (Figure 2B). The CoV 
membrane fusion process is initiated by a further S2’ cleavage. Traditionally, the study 
of S protein structures was limited to stable small protein fragments that accommodates 
X-ray crystallography (103–107). In recent years, the advancement of single-particle 
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cryo-electron microscopy has enabled the elucidation of the native S protein trimeric 
structure in several CoV species (Figure 3), providing ample novel insights into the 
structural mechanism of S protein functions (108–114), including ones that may enable 
CoV zoonosis. 
Spike Protein is the Major Determinant of CoV Tropism 
CoV Spike Receptor-binding Domains 
The key contributor to the high propensity CoVs have for zoonotic transmissions 
could lie within the S1 subunit of the S protein. Recent structural studies have 
determined that S protein S1 subunit displays a multidomain architecture (Figure 4A 
and B). For beta-, gamma-, and delta-CoVs, their S1 subunit is structurally organized in 
four distinct domains A, B, C, and D (110, 115, 116). Alpha-CoVs appear to have an 
additional domain N-terminus of A designated as domain 0 (109, 117). Based on the 
trimeric S structure, the solvent-exposed domains A and B (for alpha-CoV, domains 0, 
A, and B) may serve as independent receptor-binding domains (RBDs). All identified 
domain A to date resemble a galectin-like structure (104, 105, 116, 117, 108–115), 
consisting of a beta-sandwich core structure with additional components (a mixture of 
secondary structures and flexible loops) around it. It has been proposed that ancestral 
CoVs likely have acquired a host galectin via gene capture, which served as the 
structural basis for domain A (118). Alpha-CoVs domain 0 is structurally analogous to 
domain A (109, 117), hence could have originated from a domain duplication event. 
Domain B, on the other hand, contains a structurally conserved core of antiparallel beta-
sheets, decorated with an extended loop on the viral envelope-distal side (103, 106–
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108, 110, 115, 116). This loop may differ greatly both in size and in structure across the 
spectrum of CoVs, and hence is also referred to as the hypervariable region (HVR). In 
contrast to domains A and B, domains C and D consist of much smaller beta structures 
and are positioned away from the target cell during entry. When in the native trimeric 
form, however, they are in close contact with the S2 subunit (Figure 4A), including the 
fact that domain D ends with the S1/S2 cleavage site. It is therefore proposed that 
domains C and D could play crucial roles in relating the structural transitions, which are 
initiated by the host receptors interacting with the target cell-facing domains A and B, to 
S2 to enable membrane fusion. 
S1 atomic structures suggest that domains A and B (and 0 for alpha-CoVs) may 
function as independent RBDs. While having such independently-positioned RBDs is a 
unique CoV feature, if and how this feature is related to the apparently high propensity 
for CoV zoonosis has been unexplored. One reason could be the technical difficulties. 
All present-day CoVs have narrow host ranges, but this is likely due to years of viral 
adaptations to a specific host, which would result in a loss of zoonotic characteristics. 
One intuitive advantage of having multiple RBDs is the associated expanded surveying 
capability of potential receptors upon transmitting to a new host. Interestingly, we do 
observe characteristics on present-day CoVs that support this putative function. First, 
different CoVs have adapted to use different RBDs as their primary receptor-engaging 
domains. CoVs such as murine hepatitis virus (MHV), bovine (B-) CoV, OC43-CoV, and 
infectious bronchitis virus (IBV) have evolved to use domain A for receptor-binding (104, 
105, 113, 119). Conversely, CoVs including NL63-CoV, SARS-CoV, MERS-CoV, and 
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porcine deltacoronavirus (PDCoV) have opted to engage their primary receptors with 
domain B (103, 106, 107, 120). It is clear that, depending on the CoV, different RBDs 
can be relied on to develop optimal interactions with receptors. Therefore, even though 
contemporary CoV tropisms are more restricted to their existing RBD-receptor 
interactions, their ancestors may have benefited from having multiple RBDs to engage 
the optimal receptor upon first entering the new host. 
The utilization of CoV spike receptor-binding domain A. Another reasonable 
expectation for the likelihood of expanded receptor-surveying with multiple RBDs is that 
each RBD may have different predispositions toward different host ligand types. This 
has been, as expected, observed to be the case. Presumably due to its close 
resemblance to human galectins (121), domain A, when adapted as the primary CoV 
RBD, tends to bind host carbohydrates, specifically sialic acids (105, 113, 119). B-CoV 
and OC43-CoV use their domain As to engage host 9-O-acetylated sialic acids as 
receptors (105, 113), whereas IBV domain A binds host receptor alpha-2,3-linked sialic 
acids (122, 123). One interesting point is that the sialic acid binding site on domain A is 
different from the beta-galactoside binding site on galectins, as a recent OC43 S-sialic 
acid cryo-EM co-structure has shown (113). Presumably, after genetically capturing the 
galectin structure from its host, ancestral CoVs have modified its ligand specificity for 
their own purposes.  
When CoV S protein domain A is used to engage the primary receptor, the 
receptor is usually sialic acid, except in the case of MHV. Instead, MHV S domain A 
engages a protein, murine carcinoembryonic antigen-related cell adhesion molecule 1a 
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(mCEACAM1a), as the principle receptor for the virus. Remarkably, the mCEACAM 
binding site on MHV domain A structurally overlaps with the sialic acid binding site on 
OC43 domain A (104, 113). This could suggest a possible evolutionary trajectory where 
the ancestral MHV had adapted its domain A for a protein receptor and through this 
adaptation, had gradually lost its sialic acid binding capabilities (105). Indeed, the S 
proteins of several MHV strains lack detectable sialic acid interactions (124), and are 
commonly used as negative-controls in research (105, 125, 126). On the other hand, if 
we accept that the protein-binding MHV domain A had evolved from a sialic acid-binding 
ancestor, then there should be an evolutionary intermediate, where the domain A binds 
to sialic acids as well as a protein (Figure 4C). A CoV with a domain A of this 
“intermediate phenotype” may have an expanded tropism, or rather, the tropism of this 
CoV cannot be fully accounted for by the availability of its protein receptor. Surprisingly, 
this description coincides with the phenotype of MHV strain JHM. Like other MHV 
strains, JHM engages its principle receptor, mCEACAM1a, via domain A. Unlike other 
strains, where the virus kills the host due to liver damage (hence the naming of the 
virus), JHM eliminates the host via brain damage. It has been further elucidated that 
their S proteins are the main determinants for these phenotypic difference (127–129). 
Interestingly, compared to the liver, mCEACAM expression in the mouse brain is very 
low (130). Conversely, neuronal cells are known for their abundance in sialic acids 
(131). Additionally, the presence of JHM S protein alone is sufficient for the virus to 
infect mCEACAM1a knock-out mice (129). 
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Figure 4. Coronavirus S1 Subunit. (A) MHV (PDB: 3JCL) S is depicted as in Figure 3, 
with additional color coding of the S1 sub-domains. (B) S1 extract from panel A, with 
sub-domains color coded (red, domain A; orange, domain B; green, domain C; blue, 
domain D). (C) Proposed CoV S1 domain A evolution. Ancestral CoV might have 
acquired a galectin structure from its host, and adapted to bind different sugar moieties. 
Ancestral MHV may have further diverged and evolved protein-binding potentials. An 
evolutionary intermediate was proposed to interact with both host sugar and protein 
factors. Galectin-3 crystal structure (orange) was obtained from PDB: 1A3K. BCoV S 
domain A crystal structure (blue) was obtained from PDB: 4H14. MHV-A59 S domain A 
cryo-EM structure (red) was obtained from PDB: 3JCL. The mock structure for the 
intermediate was a recolored version of MHV-A59. (D) MERS S (PDB: 5X5F) S1 is 
shown in surface representation, oriented similar to panel B. The S domain B is 
depicted in both down (green) and up (cyan) conformations. 
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Even though the exact mechanism JHM S utilizes to infect the brain has not been 
resolved, it is possible that JHM S domain A could engage host mCEACAM1a as well 
as sialic acids. 
The utilization of CoV spike receptor-binding domain B. Different from S 
protein domain A’s general predisposition towards host sialic acids, domain B, when 
used to engage the primary receptor, the receptor is always a host protein. 229E-CoV, 
transmissible gastroenteritis virus (TGEV), and feline infectious peritonitis virus (FIPV) 
use their domain Bs to engage host aminopeptidases N (APN) as receptors (132–135). 
NL63-CoV, SARS-CoV, and likely Wuhan-CoV domain Bs bind to host receptor 
angiotensin-converting enzyme 2 (ACE2) (103, 107, 136). The domain B of MERS-CoV 
engages host receptor dipeptidyl peptidase IV (DPP4) (106, 137). Interestingly, domain 
B appears to have a bias towards recognizing these peptide-processing exopeptidases 
as receptors, without relying on their enzymatic activities. This bias evidently was 
prominent enough to result in convergent evolution, where both NL63-CoV and SARS-
CoV have adapted to use ACE2 as the receptor, but they achieved this by evolving 
unique contact motifs on their domain Bs (103, 107). While we do not know all the 
advantages of CoVs using these exopeptidases as receptors, they may be related to 
their proximities to other, required, co-factors for CoV entry. Indeed, one study has 
shown that hDPP4 is likely in the same host plasma membrane microdomain as some 
type II transmembrane serine proteases (TTSPs), whose cleavage activities drive facile 
MERS-CoV entry kinetics (138). 
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As a prerequisite to infection, viral glycoproteins engages their receptors. This 
receptor-ligand interaction is believed to impose certain structural properties on the 
glycoprotein, which primes the glycoprotein for subsequent steps toward membrane 
fusion. The documentation of these effects, however, can be challenging. One of the 
few cases where these structural changes were well characterized is in the case of HIV-
1 gp160 (139), and more recently for EBOV GP (140). It was revealed via single-
molecule Förster resonance energy transfer (FRET) that the gp160 native trimer is 
structurally dynamic, transitioning through multiple prefusion conformations. Importantly, 
receptor engagement stabilized gp160 to particular conformations that favor 
downstream events (139), which has been verified through recent structural studies 
(83). Interestingly, we see a similar theme in CoVs. CoV S protein domain B, as well as 
domain A, engages host receptors and potentiates the S protein for proteolytic 
cleavage, which facilitates viral fusion. How this signal is relayed structurally has been 
unclear, but recent cryo-EM advances may offer some insight. It has been noted that 
the domain B-receptor affinity is higher when soluble domains are used than the native 
S trimers. This is because, in the native state, the domain B receptor-binding motif is 
shielded from interactions with the protein receptor (109, 112). Therefore, by extension, 
domain B would need to go through structural transitions to reveal this binding motif 
before receptor engagement. Indeed, the domain B of MERS S and SARS S have been 
observed to spontaneously transition between the receptor-unresponsive “down” state 
and the receptor-responsive “up” state (Figure 4D). Interestingly, this domain B 
structural transition appears to be linked to the overall stability of the spike trimer. While 
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cryo-EM readily obtained native S trimer structures with zero, one, or two domain Bs in 
the “up” state (111, 112), the structure with all three domain Bs in the “up” state could 
only be obtained using an unfusogenic S that has been stabilized in the S2 region (141). 
These results support a model where the native S trimer is maintained stable as long as 
some of the domain Bs are in the “down” state. When a domain B engages with the 
protein receptor, their high affinity interaction holds the domain in the “up” state. When 
all three domain Bs are “up”, there is a significant reduction in the contact residues 
between S monomers, which may result in S1 timer destabilization. The S proteins in 
this metastable state may be prone to proteolytic cleavages, which unleashes the series 
of structural transitions that facilitate membrane fusion, and finally land in the hyper-
stable post-fusion conformation. Indeed, the highest proportion of S post-fusion 
conformations were obtained when the native S trimers where coincubated with an 
antibody that maintains the SARS S domain B “up” state, and exogenous proteases 
(141). While the specific structural transitions domain A may elicit upon receptor 
engagement is currently unclear, it is possible that both domains converge on the 
domain B “up” state to prime S for viral fusion. 
The dual-utilization of CoV spike receptor-binding domains. Even though 
having multiple RBDs may offer major advantages in receptor surveying during the 
initial stages of CoV cross-species transmissions, other benefits may exist as well. Most 
contemporary CoVs, which have fully adapted to their biological niches, still retain all of 
their RBDs. 229E-CoV appears to have lost its domain 0, the putative sialic acid-binding 
domain for alpha-CoVs, but this is a very rare phenomenon for CoVs (133). Because 
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CoVs generally evolve one RBD to engage with the primary receptor, it is possible that 
the other RBDs can be adapted to acquire secondary benefits. Indeed, two such 
examples exist: MHV and MERS-CoV. All MHVs use their S protein domain As to bind 
to the protein receptor mCEACAM, while to this day no factor was ever identified to 
engage their domain Bs. Instead, MHV domain B has been observed to modulate the 
stability of the S trimer and modulate the energy thresholds for S-mediated membrane 
fusion activation (142–145). MHV-JHM has a very unstable S protein, in that its S1 can 
be found to dissociate from S2 from incubation at physiological conditions (pH=7, 37°C) 
(146). Because S1-S2 dissociation is considered a prerequisite for S-facilitated 
membrane fusion, this S protein instability has been viewed as a requirement for the 
unique entry properties of JHM-CoV. Interestingly, JHM has the largest domain B of all 
MHVs. While JHM maintains its domain B size when grown in the mouse brain, large 
domain B deletions (up to ~150 residues) arises upon in vitro passaging of the virus in 
cell cultures (142, 145, 147). The decrease in domain B size corrected with the 
decrease in JHM neurovirulence, S1-S2 stability, and the mCEACAM-independent 
activities (146). These results suggest that, when a domain B is not used to engage 
receptors, it can nonetheless be adapted to provide certain structural segues for 
membrane fusion. These structural segues could be the very same ones observed for 
MERS-CoV and SARS-CoV, where domain B spontaneously transitions between “up” 
and “down” conformations (Figure 4D). Intriguingly, even though JHM receptor-binding 
occurs on the domain A, which is distally-positioned from domain B, its receptor-
engagement may still be connected to the domain B-mediated S instability. The support 
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for this came from early mutagenesis studies, where the linker region between domain 
A and B was found to affect the same JHM properties as its domain B sizes (148). It 
was, therefore, suggested that the signal of domain A-receptor-engagement is 
transmitted, structurally, to other parts of the S protein (presumably to domain B). 
Another example where CoVs utilize both RBDs is the MERS-CoV. MERS-CoV 
engages its protein receptor, DPP4, with the S protein domain B, the virus has also 
evolved to utilize its non-receptor-binding domain, domain A, to aid in the viral infection. 
Perhaps the strongest evidences that MERS domain A is important for MERS-CoV 
infection are the demonstrations that antibodies against this domain can be neutralizing 
(149–151), and protected model mice from lethality (151). The mechanistic function of 
MERS domain A was revealed in a recent study. Specifically, MERS-CoV was found to 
bind host sialic acids, and this interaction was narrowed to its S protein domain A. 
Interestingly, unlike the strong sialic acid-binding domain As of B-CoV and OC43, the 
weak interactions between MERS domain A and sialic acids were not detectable using 
soluble domain, and only after multimerically appended onto nanoparticles can they be 
quantified (126). The report also identified the specific ligand to be α-2,3-linked, 
unacetylated sialic acids (126). Furthermore, the MERS domain A sialic acid binding 
pocket was visualized in a cryo-EM study to be at the same location on domain A as 
OC43 (113, 114). Despite being a relatively weak interaction, the engagement between 
MERS S domain A and host sialic acids appears to be a mechanistically relevant one, 
for sialic acid depletion significantly reduced MERS S-facilitated pseudovirus and 
authentic virus entry (114, 126), even though the target cells expressed sufficient levels 
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of hDPP4. These results support an infection model where CoVs, such as MERS, can 
differentially utilize strong interactions (e.g. domain B and hDPP4) for infection, and 
weak interactions (e.g. domain A and sialic acids) for host attachment. In this model, the 
viral tropism is determined by the host interactions with both RBDs. While it is widely 
accepted that strong receptor interactions enable viral infection, it is not clear, however, 
to what extent weak S-host interactions can achieve. More targeted studies where the 
host interactions with each CoV RBD can be investigated in isolation would offer 
additional enlightenment with respect to the contribution of each interaction to the viral 
tropism on the whole. 
CoV spike receptor-binding domains enable viral zoonosis. CoV infections 
are generally restricted to their specific host species. As zoonotic pathogens, however, 
CoVs may occasionally cross the species barrier and expand their tropism within a new 
host. Often, the virus will replicate but fail to transmit to new members of the species, 
and eventually be eliminated. Sometimes, the virus will evolve within this host and 
become transmissible to other members of the same species. Overtime, the virus will 
become endemic to the new species. The host requirements for CoV zoonosis, thus far, 
have been centered around the utilization of orthologous receptors. SARS-CoV uses its 
S domain B to engage its primary receptor, hACE2. One strong supporting result for the 
viral zoonosis trajectory being from bats to civets and then to humans is that the virus 
can bind to the ACE2 from any of these species to enable infection. Remarkably, 
structural studies allowed us a glimpse into this zoonotic event. Among the contact 
residues between human (h) SARS-CoV and hACE2, civet (c) ACE2 differed at one 
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residue, which reduced its binding to hSARS-CoV. Conversely, this variance was 
compensated by a point mutation in cSARS-CoV, restoring the S-ACE2 affinity. 
Additionally, mouse (m) ACE2 contains a residue change that eliminates a critical 
interaction with hSARS-CoV. Through forced viral adaptation, mSARS-CoV mutated a 
residue which partially-compensated for the missing interaction to mACE2 (reviewed in 
(152)). These results demonstrate that the interactions between orthologous protein 
receptors and S protein domain B can be sufficient to enable CoV cross-species 
transmission. On the other hand, sialic acid-S domain A interactions have also been 
implicated to be sufficient for zoonosis. B-CoV had been endemic only in cattle, until 
around the 1890s, when the virus crossed the zoonotic barrier and spilled over into 
humans (38). After adaptations in humans (153), the resulting CoV, OC43, eventual 
became endemic in humans (16). Current B-CoV and OC43-CoV share remarkable 
similarities of up to 96% nucleotide identity (38), suggesting that they likely also share 
common mechanisms of transmission. Indeed, both B-CoV and OC43 engage their 
common receptor, 9-O-acetylated sialic acids, with their S protein domain As to facilitate 
membrane fusion (105, 113, 125). Therefore, common sialoside receptors may enable 
CoV zoonosis, via domain A interactions. The third scenario where zoonosis may be 
achieved appears to require both appropriate domain A and domain B receptor 
interactions. MERS-CoV is considered to have originated from bats (52), which passed 
to camels (49), which then passed to humans in 2012 (26, 31). MERS-CoV S protein 
domain B engages its principle protein receptor, hDPP4 (106), whose orthologue 
utilization appears to be sufficient to convey susceptibility. Indeed, in cell cultures, 
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MERS S engages DPP4 orthologues from human, camel, bat, goat, sheep, horse, 
rabbit, and pigs, and but not mouse, hamster, and ferret, for infection (154, 155). 
Remarkably, among these putatively susceptible species, horses, goats, sheep, pigs, 
and rabbits are generally found to be sero-negative for the virus (156–158). These 
differences suggest that there are factors other than DPP4 that could function as 
zoonotic barriers. In addition to its domain B interactions with DPP4, MERS S domain A 
also engages target cell α-2,3-linked sialic acids (126). The presence of this glycotope 
in the gastrointestinal/respiratory tract indeed correlates well with the susceptible animal 
species of bats, camels, and humans, while it is absent in the non-susceptible horses, 
pigs, rabbits, and sheep ((159), and reviewed in (160)). Further evidence for host sialic 
acids potentially functioning as zoonotic barriers is provided by forward genetic studies. 
During the adaptations of MERS-CoV to two independently-developed humanized mice 
models, the virus fixed an adaptive mutation at Asn222, located on the apical side of the 
sialic acid-binding S domain A (161, 162). Even though Asn222 is located outside of the 
identified sialic acid binding site on MERS S domain A (114), it does fall within a cluster 
of residues that have been shown to allosterically affect the sialic acid binding of related 
viruses (105, 125). Studies that aim directly at the sialic acid interactions of the mutant 
MERS S domain A would shed light on the relationship between host sialic acids and 
CoV cross-species transmissions, in addition to requiring appropriate S domain B-DPP4 
interactions. Without a doubt, MERS S domain A is under active selection, as Asn222 is 
among a hand full of domain A variants whose nucleotide polymorphisms were detected 
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in a recent survey of circulating MERS-CoV strains in human populations of Saudi 
Arabia (163). 
Through the utilization of multiple RBDs, CoVs acquire specific zoonotic niches. 
These utilizations may involve specific sialic acid receptors (e.g. B-CoV, OC43-CoV), 
protein receptors (e.g. 229E-CoV, SARS-CoV), or both (e.g. MERS-CoV), as well as 
resulting in fine-tuned S protein stabilities (e.g. MHV). Exploring answers to remaining 
questions, such as whether bi-valent RBD exists, or a possible sequential functioning of 
the RBDs during CoV entry, or whether some RBDs are truly vestigial, can greatly 
enrich our understanding of CoV biology, and bringing us closer to constructing 
appropriate strategies to combat the threat of CoVs to global health, as the ongoing 
SARS-CoV-2 outbreak escalates. 
CoV Spike Membrane Fusion Mechanism  
CoV spike membrane fusion is triggered by proteases. Viral entry is a highly 
regulated process, for it governs viral tropism. Therefore, it is not uncommon for viruses 
to utilize additional host factors as triggers for membrane fusion, even after receptor 
engagement. IAV HA, after engagement with its sialic acid receptors, requires a low pH 
environment to initiate membrane fusion (71, 74). VSV glycoprotein (G) engages low-
density lipoprotein receptors (LDLRs) for entry, but membrane fusion is not initiated until 
the low pH stimulation following endocytosis (80, 164). While CoV S protein S1 subunit 
governs host attachment, the S2 subunit facilitates virus-target membrane fusion. 
Structurally, S2 is shielded by S1, therefore, this restraint would need to be lifted for 
membrane fusion. S1 receptor engagement destabilizes S1-S2 interactions (141, 143, 
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165, 166), but to dissociate S1 from S2, CoVs further require host proteases to cleave 
at the S1/S2 junction (Figure 5). Depending on the specific amino acid sequences, the 
region downstream of S1 domain D may have different susceptibilities to the various 
host proteases. For MHV-JHM and MERS-CoV, their S1/S2 site is so sensitive to 
proteases, that the majority of their S proteins are cleaved during viral assembly in the 
infected cell and so S1 is only non-covalently associating with S2 on the mature virion 
(146, 167). After these virions engage with receptors on the new host, there is only one 
additional proteolytic cleavage event required to trigger fusion. The S proteins of MHV-
A59 and SARS-CoV, on the other hand, are much more resistant to host proteases, so 
that the S1/S2 junction remains largely intact on the mature virion (167, 168). To infect, 
these virions would require the S1/S2 cleavage after receptor engagement on the new 
host, before advancing to the next stage. 
After the S1-S2 dissociation, it is expected that all CoV S proteins require a final 
cleavage event to enable membrane fusion. This second cleavage site in located 
immediately upstream of the fusion peptide, termed the S2’. Unlike the S1/S2 cleavage 
site, which is putatively accessible to host factors including proteases, the S2’ site is 
buried within an α-helix and not exposed in the pre-fusion conformation (110, 141). This 
suggests the requirement of extensive S conformation changes before S2’ cleavage, 
presumably the structural destabilization from receptor engagement, and the S1 
dissociation from S1/S2 cleavage.  
32 




Figure 5. Coronavirus S2 Subunit. S2 structural transitions during CoV entry. CoV 
entry is depicted as shown in Figure 2B. During host attachment, CoV S protein subunit 
S2 (gray) is shielded by S1 (yellow) in the pre-fusion conformation (top-left). Cryo-EM 
structure of MHV S (PDB: 3JCL) pre-fusion conformation is used as an example. 
Receptor engagement potentiates the dissociation of S1 from S2, revealing S2 for 
proteolytic processing (top-middle). The unshielded S2 Structure is modeled by 
extracting S2 from the trimeric S structure in panel A. Proteolytic cleavage triggers 
drastic S2 conformational changes, which facilitated membrane fusion and results in a 
stable helix-helix bundle that is the post-fusion conformation (top-right). MHV S post-
fusion structure (PDB: 6B3O) is used as an example. 
 
Even though the specific structural transitions after the S2’ cleavage have not been 
observed, it is generally believed that this cleavage would release the tension holding 
four short α-helices in place, and they instead would join and refold into a long trimeric 
coiled coil, with the fusion peptide positioned at the distal end, projected towards the 
target membrane (99, 100). Thereon, with success, the fusion peptide will be embedded 
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into the target membrane, physically bridging the two membranes (Figure 5). Next, a 
part of the long coiled coil, termed the heptad repeat region 1 (HR1), through extensive 
hydrophobic interactions with the downstream helical HR2 (169), pulling the two 
membranes into close apposition to catalyze fusion (Figure 5). 
CoV spike proteolytic sensitivity dictates entry kinetics. Because of the 
absolute requirements of the S1/S2 and the S2’ cleavages, host proteases are obligated 
factors for CoV entry. And because of the intrinsic viral sequence differences at these 
cleavage sites, as well as the inherent variations in the availability of the various host 
protease types, it is only natural to conclude that these proteases form another class of 
entry factors that, potentially, dictates CoV tropism, pathology, and zoonosis. Indeed, 
the MHV-2 and SARS-CoV S1/S2 cleavage sites are insensitive to furin, the major and 
most well-characterized serine proprotein convertase (170). As the result, when these 
viruses bind to receptors on target cells, their S proteins still require two cleavage 
events before entry can be completed. Presumably because two cleavages per S is 
beyond the capability of cell surface proteases at physiological levels, these CoVs are 
obligatory endocytic viruses, where endocytosed virions encounter high levels of 
endosomal cysteine proteases in the cathepsin family (167, 171, 172). After cleavages 
at both S1/S2 and S2’ by endosomal cathepsins, these particles complete viral entry. 
Conversely, the S1/S2-cleaved S proteins on MHV-JHM and MERS-CoV only need one 
additional cleavage (S2’) before membrane fusion. In these cases, cell surface 
proteases such as the transmembrane protease, serine 2 (TMPRSS2), a representative 
TTSP, is sufficient to cleave at S2’ and allow these viruses compete entry at or near the 
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cell surface (138, 161, 173, 174). While entry in the endosome and at the cell surface 
both are explored by CoVs (Figure 6), cell surface entry does offer a few advantages. 
First, surface entry is more kinetically favorable than endosomal entry. Studies have 
determined that MERS-CoV can entry target cells four times faster when using the cell 
surface route, with 50% viral entry at ~15 min vs. ~60 min for endosomal entry (138, 
161, 174). With a more facile entry kinetics, these CoVs presumably establishes 
infection in a more competitive manner. Second, surface entry potentially avoids innate 
antiviral factors. These include the endosomal RNA sensors, which could potentially 
alert the host innate immune system, which compromises CoV infections (175). Another 
class of innate antiviral factors are the interferon-induced transmembrane proteins 
(IFITMs). These small (~140 residues) single-pass transmembrane proteins somewhat 
non-specifically inhibit viral-induced membrane fusions, including IAV, VSV, WNV, 
EBOV, HIV, SARS-, and MERS-CoV (176–181). Third, endosomal entry is time-
sensitive. Because the endocytic pathway is used for digestion, it is an intuitive dead 
end for viral entry. In an event where a virion moves too far down the endocytic process, 
the late-endocytic / lysosomal digestive enzymes will excessively proteolyze and 
destroy the infectious agent. Hence, cell surface entry may be relatively protective to the 
virion. Conversely, the utilization of the endocytic entry route may be a byproduct from 
specific CoVs developing the S protein stability needed for efficient viral transmission. 
With S1/S2 uncleaved, the S protein of SARS-CoV is more stable than the S1/S2-
cleaved MERS-CoV.  
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Figure 6. Coronavirus Entry Routes Depend on Protease Utilization. To facilitate 
fusion between the CoV envelope and the target cell membrane that is the pinnacle of 
viral entry, CoV S proteins requires activation by proteases. Because of this, the specific 
subcellular location at which membrane fusion is completed during CoV entry is directly 
related to the level of suitable proteolytic activities at these locations. Hence, CoV entry, 
depends on the proteases present, can either be completed at or near the plasma 
membrane or within the endosome after endocytosis. If the target cell expresses high 
levels of cell surface serine proteases such as hTMPRSS2, sufficient cleavage events 
can happen at the S1/S2 and/or S2’ sites on the S protein. In this scenario, the 
utilization of hTMPRSS2 skews the CoV entry site towards plasma membrane. 
However, if the target cell expresses insufficient levels of hTMPRSS2, or the S protein 
in question does not contain an optimal peptide sequence for hTMPRSS2 cleavages, 
the entry process may not be facile enough to be completed at or near the plasma 
membrane. Because the virus would most likely remain bound to the cell due it the high-
affinity interactions between S and the receptor, the virion would mostly likely be 
endocytosed and trafficked into the endosome. As the virus progresses through the 
endocytic pathway, it would encounter the resident cysteine protease cathepsins. For 
most CoV S proteins, endosomal cathepsins are also able to cleave and trigger S 
conformational changes needed for membrane fusion. Because cell surface entry is 
kinetically more facile than endosomal entry, these entry pathways are also referred to 






   
 
 
This correlated with the epidemiological determination of their transmission rate and 
basic reproduction numbers (R0), where R0(SARS) > 1, a highly-transmissible virus, and 
R0(MERS) < 1, a low-transmission virus (28, 32).  
CoV tropism depends on protease utilization. While entry route preferences 
may lead to entry kinetic differences, it is the variation in the requirement of different 
host protease types that drives CoV tropism diversity. Additionally, there may be more 
CoVs that utilize the cell surface entry route than currently characterized, because the 
laboratory environment tend to skew CoVs towards the endocytic entry route. 
Laboratory-adapted 229E-CoV reportedly uses the endocytic route, whereas Shirato et 
al. demonstrated that the 229E clinical isolates preferred the cell surface route, and it is 
the cleavage site mutations arose during laboratory passages of the virus that 
accounted for this phenotypic difference (182). Importantly, the 229E clinical isolates 
preferentially utilized cell surface proteases, such as TMPRSS2, for entry, and 
replicated to higher titers in human airway epithelial (HAE) cell cultures, the best 
mimicry to the human bronchial environment to date. Conversely, the laboratory-
adapted virus yielded higher titers in cell cultures with low levels of surface TMPRSS2, 
and instead preferred to use endosomal cathepsins for entry (182). Therefore, the 
reliance on cell surface proteases correlated with the natural tissue tropism of 229E-
CoV. Moreover, one of the results supporting the bat origin of MERS-CoV is the finding 
that the virus can use bat (b) DPP4 and infect bat cells (52, 183). Interestingly, however, 
the most closely-related MERS-like CoVs in bats, HKU4-CoV, cannot infect human 
cells, even though HKU4 can bind to hDPP4 (52, 183). Remarkably, two residue 
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substitutions that made the HKU4 S1/S2 cleavage site more MERS-like enabled HKU4 
S-facilitated viral entry into human cells (184). Taken together, these results suggest 
that the diversity in the utilization of different host proteases during viral entry may not 
only affect specific CoV tissue tropism, but also dictate the likelihood CoVs can achieve 
cross-species transmissions, or zoonosis. 
Coronavirus Spread 
Existing CoV infections can be spread through two different mechanisms. First of 
all, new viruses assemble and bud into the endoplasmic reticulum—Golgi intermediate 
compartment (ERGIC) of the infected cell (185, 186), facilitated by the retention signal 
sequences in the M protein (1, 6), as well as the interactions between M and N (1, 3). 
Mature virions are eventually released out of the secretory pathway and into the 
extracellular space (Figure 7), where they are passively brought to close proximity to 
naïve cells, and, if successful, another round of infection is initiated via canonical CoV 
entry. Alternatively, established CoV infections can be transmitted directly into 
neighboring cells, without the need for manufacturing de novo virions. This is achieved 
through the process of cell-cell fusion, or syncytia formation (Figure 7). This process is, 
mechanistically, facilitated by the S proteins decorating the plasma membrane of the 
infected cell. Through the interactions with factors on the neighboring cell plasma 
membrane (e.g. receptor engagement, protease cleavage), these cell-bound S proteins 
go through structural transitions and facilitate membrane fusions analogous to canonical 
CoV entry. Once the fusion pore is formed, the CoV genome can diffuse into the naïve 
cell cytoplasm and expand the infection (Figure 7).  
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Figure 7. Coronavirus Infection Spread. CoVs use two methods to spread existing 
infections, either through the canonical viral assembly and release, which initiates de 
novo infections using receptors and proteases, or the same host factors can be 
engaged by S proteins on the infected cell surface and spread the infected directly into 
neighboring cells, via the process of cell-cell fusion, or syncytia formation. 
39 
   
 
 
Perhaps because the fusion requirements do not include any obligatory endocytic 
elements such as low pH stimulations, this ability to facilitate cell-cell fusion appears to 
be a universal trait for CoVs, as it has been documented for a wide range of S proteins 
(143, 187–195). 
The mechanisms by which CoVs spread existing infections intercellularly, may 
explain, in part, the remarkable expansion of these viruses into new hosts, including 
humans. It is generally accepted that cell-cell fusion requires the same set of triggers as 
virus-cell fusion, which includes RBD-receptor interactions, followed by proteolytic 
cleavage(s). However, whether these factors are needed to the same extent remains an 
open question. Intuitively, unlike in virus entry, where virions are diffused in the 
extracellular space and hence first require membrane anchorage, cell-cell fusion do not 
have the requirement for this cell attachment. Instead, the membrane of the S-
expressing cells are naturally in close proximity to the neighboring cell membranes. 
Additionally, an individual CoV virion has a finite number of S proteins to facilitate entry, 
whereas an infected cell replenishes its surface S proteins continuously. Due to these 
characteristic differences, one may expect the way CoV cell-cell spread utilize host 
factors to be relatively different. Perhaps certain modest interactions between S and the 
target cell (i.e. with sialic acids) may be sufficient to advance to cell-cell membrane 
fusion. 
Amongst the CoV cell-cell fusions, the ones caused by the S protein of MHV-
JHM stands out. Unlike the S protein from other CoVs, or even from other MHV stains, 
the S protein of JHM has been documented to facilitate cell-cell fusion independent of 
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its principle protein receptor, mCEACAM1a, resulting in the fusion between mCEACAM+ 
and mCEACAM- cells, even if these cells originated from different animal species (143, 
144, 188, 196, 197). Additionally, JHM-CoV is the only MHV strain known for causing 
lethal brain infection, even in mice that lack CEACAM1a (129).  JHM spike was 
identified to be the major contributor to this phenotype (129), and JHM-CoV, but not the 
related A59-CoV, spread inter-neuronally both in vivo and within in vitro cultures of 
CNS-derived cells (198, 199). Moreover, these cell-to-cell syncytial spread correlates 
with pathogenesis in several infection models (129, 188, 200–203). However, the 
mechanism for this protein receptor-independent JHM spread is unclear. Because JHM 
S domain A engages mCEACAM1a while its domain B has been not been shown to 
engage any host factors, but instead functions to lower the energy barrier for S 
conformational changes (143, 146), it was proposed that JHM S does not need to 
engage with receptors to fuse cells. An alternate hypothesis is that JHM S has weak 
interactions with a host factor that is more promiscuous across different animal species. 
Sialic acids are good candidates, especially since the structure of MHV domain A highly 
resembles those of the sialic acid-binding relatives (104, 105, 113). Notably, neural cell 
membranes are known for their abundant sialic acid content (131). Therefore, a JHM S-
sialic acid binding can potential accounts for an inter-neuronal syncytial spread that is 
rapidly lethal. A prediction is that variants of JHM-CoV exhibiting enhanced sialic acid 
affinity will have unusually high neurovirulence. On the other hand, the pathological 
impacts from cell-cell fusion have not been well studied for other CoVs, mainly due to 
the limitations in non-mouse animal studies and the lack of human biopsies. Because 
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cell-cell fusion potentially amplifies the effects of weak S interactions, it may be in this 
context can the link between certain host factors and pathogenesis be characterized. 
MERS-CoV strain causes lethal pneumonia and here it is significant that antibodies 
specific for the MERS-CoV S domain A both neutralize the virus and reduce infection 
and pathogenesis in a mouse MERS-CoV model system (149, 151, 204).  Because 
MERS S domain A has weak interactions with host sialic acids, conceivably, these 
antibodies interfere with sialic acid binding, reducing expansion of MERS-CoV that may 
take place via cell-cell fusion. Variants of MERS-CoV with enhanced cell-binding may 
be useful in assessing the in vivo significance of these interactions. 
Purpose of Dissertation 
A review of the literature shows that CoVs utilize multiple host factors to spread 
their infections. These include viral attachment factors, receptors, and host proteases. 
While the involvement of these factors have been characterized, our knowledge is 
lacking when it comes to the extent any particular factor contributes to the fusion 
process as a whole. Additionally, past studies have focused on CoV virion entry, leaving 
the cell-cell fusion mode of infection transmission largely unexplored. Our goal was to 
use reductionist approaches to investigate the involvement of each host factor in 
isolation, at each step of CoV entry and spread. 
We hypothesis that distinct RBDs operate at different CoV infection stages. Initial 
infection by virus particles likely requires weak associations with the target cell, before 
durable interactions with cell receptors are needed for entry. At later infection stages, 
CoVs produce S proteins in abundance, far exceeding the amounts that are 
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incorporated into secreted progeny virus particles.  These unincorporated S proteins 
accumulate on infected-cell plasma membranes, where, depending on the CoV strain, 
they mediate cell-cell fusions, i.e., syncytial developments, which rapidly expand 
infection. Close cell-cell contacts may obviate the need for high-affinity adherence of S 
proteins to adjacent, uninfected cell surfaces.  Conceivably, S domain A RBDs with 
relatively low affinity for sialic acids might be sufficient to promote syncytial expansion of 
infection, without requiring high-affinity domain B protein receptor interactions. This 
putative role for sialic acids has yet to be tested. This study provides results that 
implicate sialic acids in facilitating CoV infection and CoV cell-cell spread, bringing 





MATERIALS AND METHODS 
Cells 
HEK293T (ATCC), HeLa (ATCC) and HeLa-mCEACAM (205, 206) cells were 
maintained in DMEM-10% FBS media [Dulbecco’s Modified Eagle Media (DMEM) 
containing 10 mM HEPES, 100 nM sodium pyruvate, 0.1 mM non-essential amino 
acids, 100 U/ml penicillin G, and 100 µg/ml streptomycin, and supplemented with 10% 
fetal bovine serum (FBS, Atlanta Biologicals)]. BHK-21 cells (ATCC) were maintained in 
DMEM-5% FBS media.  LET-1 cells (BEI Resources; (207)) were maintained in DMEM-
10% FBS media lacking HEPES, sodium pyruvate and non-essential amino acids.  
Calu3 cells (ATCC) were maintained in MEM-20% FBS media [Minimum Essential 
Media (MEM) supplemented with 20% FBS, 100 U/ml penicillin G, and 100 µg/ml 
streptomycin]. DBT cells (208, 209) were maintained in MEM-5% FBS media [MEM 
supplemented with 5% FBS, 10% tryptose-phosphate broth, 26.8 mM sodium 
bicarbonate, 2 mM L-glutamine, 100 U/ml penicillin G, and 100 µg/ml streptomycin]. All 
cell lines were cultured in a 5% CO2 incubator at 37°C. 
Viruses 
Recombinant MHV strains JHM.SD (210) and A59 (211), both containing a firefly 





grown in DBT cells.  Media were collected at 24- to 48-h post-infection.  JHMHE- arose 
during previous laboratory passaging of JHM.SD. 
Pseudoviruses 
HIV-based pseudovirus particles (pps) were constructed as described in (167). 
Briefly, HEK293T cells were transfected with pNL4.3-luc R- E- obtained from the NIH 
AIDS Research and Reference Protram, cat. #3418, and viral or host protein expression 
plasmids, including pHEF-VSV G-Indiana (BEI Resources), pcDNA3.1-EMC-S-C9 
(MERS S) as described in (154), and pCMV6-Entry-hDPP4FLAG (accession # 
NM_001935; purchased from OriGene), and pCAGGS-TMPRSS2FLAG (212). To 
produce fluorescently-labeled pps, expression plasmids for either S15-GFP or S15-
mCherry was included as described in (213). 6 h later, cells were replenished with 
DMEM-10% FBS. Media were collected after a 48-h incubation period. 
Vsvpps were constructed as described in (214). Briefly, HEK293T cells were 
transfected with viral glycoprotein expression plasmids, including pHEF-VSV G-Indiana 
(BEI Resources), pcDNA3.1-HA5-QH and pcDNA3.1-PR8 NA1 (obtained from Lijun 
Rong, University of Illinois—Chicago). 24 h later, cells were inoculated for 2 h with 
VSVdeltaG/Junin GP-luciferase (214, 215).  Cells were rinsed twice with FBS-free 
DMEM media and replenished with DMEM-10% FBS.  Media were collected after a 48-
h incubation period.  
Virus-like Particles (VLPs) 
CoV VLPs were constructed by co-transfection with equimolar amounts of CoV 





sequences for A59-CoV S, E, M and N genes are presented in accession # 
AY910861.1; for JHM-CoV, accession # AC_000192.1; and for MERS-CoV [EMC 2012 
strain (216), accession # JX869059.2, where only S gene is codon-optimized (154)].   
The A59 / JHM-CoV and the MERS-CoV genes were inserted into pCAGGS and 
pcDNA3.1 expression vector plasmids, respectively.   Recombinant pCAGGS-DSP1-7-
N and pCAGGS-DSP8-11-N were constructed by fusing the DSP1-7 or DSP8-11 coding 
sequences [pDSP1-7 and pDSP8-11 (217, 218) provided by Zene Matsuda (University 
of Tokyo)], followed by a 2x SGGS linker, to the 5’ end of the coding sequences for N  
genes. 
Expression plasmids (1 ug) were complexed with polyethylenimine (PEI; 
Polysciences) (6 ug) in 0.2-ml of Opti-MEM (Life Technologies) for 15 min at room 
temperature, then added dropwise to 5 x 105 HEK293T cells in 1-ml DMEM-10% FBS.  
For spikeless VLPs, S expression plasmids were replaced with empty vector plasmid 
DNAs.  6 h later, cells were replenished with fresh DMEM-10% FBS.  Media were 
collected at 48 h post-transfection.   
Particle Concentration 
Media containing viruses, pseudovirus particles, and VLPs were clarified by 
differential centrifugation (300xg, 4°C, 10 min; 3000xg, 4°C, 10 min).   Particles were 
concentrated from clarified media by overnight centrifugation (SW28, 6500 rpm, 4°C, 18 
hrs) through cushion comprised of 20% w/w sucrose in FBS-free DMEM.  The resulting 
pellets were resuspended in FBS-free DMEM, and the resulting 100x concentrated 





For particle concentration using ultrafiltration, pps were collected in SFM. After 
differential centrifugation (300xg, 4°C, 10 min; 3000xg, 4°C, 10 min), clarified 
supernatant was loaded into 10 kDa filter units (Millipore, UFC901024) and 
concentrated 100-fold, and subsequently stored at  -80°C. 
In Vitro Fusion Assay 
 S15-GFP – labeled MERS-S-HIVpps were mixed with the S15-mCherry – labeled 
hDPP4-HIVpps at 1:1 ratio. Particle binding was allowed for 30 min at 37°C. 
Subsequently, 5 µg/ml trypsin (EMC Millipore) and/or a final concentration of 1 µM 
MERS HR2 peptides (174) was added to the particle mixture, and incubated for 30 min 
at 37°C. Upon trypsin inactivation via the addition of soybean trypsin inhibitor (STI; 
Sigma), the mixture was subjected to spinoculation (1200 x g, 2 h, 4°C) to pellet virions 
onto glass coverslips (219). After fixation, GFP and mCherry fluorescent signals were 
assessed using confocal microscopy. 
 To quantify FRET induction, GFP+ mCherry+ puncta was analyzed. mCherry was 
photobleached. GFP intensities for each pucta was measured both before and after 
mCherry-photobleaching, and difference was calculated. FRET induction was signified 
by an increase in GFP emission after mCherry-photobleaching. 
Hemagglutination Assay 
Serial 2-fold dilutions of 100x concentrated virus and pseudovirus particle stocks 
were prepared using FBS-free DMEM as diluent.  Diluted samples were placed into V-





erythrocytes (in PBS) were then added and scoring was performed after 2-12 hours 
incubation at 4°C. 
Neuraminidase Treatments 
Adherent, confluent cells in 24-well plates were rinsed once with PBS before 
fixation with 3.7% paraformaldehyde in 0.159 M PIPES for 30 min at room temperature. 
Following three PBS rinses, cells were treated with vehicle or neuraminidase (1 U/ml, 
Sigma N2876) in neuraminidase buffer [200 mM NaOAc, 2mM CaCl2, pH 5.0] for 3 hrs 
at 37°C. The cells were then rinsed three times with PBS, and then blocked with PBS + 
2% FCS for 30 min at room temperature, and then used in virus binding assays.   
For live cell assays, adherent, confluent cells in 24- or 96-well plates were 
pretreated with vehicle or neuraminidase (1 U/ml, Sigma N2876) in FBS-free DMEM for 
2 hrs at 37°C.  The cells were rinsed three times with PBS, and then used in virus 
transduction assays. 
VLP Binding Assay 
VLPs used for binding assays were prepared by cotranfection with CoV S, E 
(envelope), M (matrix) and DSP1-N + DSP8-11-N encoding plasmids.  The resulting 
VLPs contained complemented DSP1-7/8-11 Rluc-positive interiors.  To quantify VLP-
associated Rluc, VLPs were serially diluted into Passive Lysis Buffer (PLB; Promega # 
E194A) and introduced into opaque microplate wells (50 ul per well).  Renilla luciferase 
substrate (1.1 M NaCl, 2.2 mM Na2EDTA, 0.22 M KH2PO4, 1.3 mM NaN3, .44 mg/mL 





luminescence read using a Veritas microplate luminometer (Turner BioSystems, 
Sunnyvale, CA). 
VLPs were incubated for 2 h at 4oC to adherent, confluent cells, either with or 
without prior neuraminidase treatments.  Incubations were in FBS-free DMEM, and at 
known Rluc VLP / cell ratios.  After incubation, unbound VLPs were removed, and cells 
were rinsed variably with PBS.  To measure cell-bound VLPs, adherent cells were 
dissolved into PLB and Rluc activity quantified. 
To quantify S protein-mediated cell binding, equivalent Rluc levels of spike-less 
(No S) VLPS were inoculated onto target cells. The resulting cell-associated Rluc signal 
in the spike-less (No S) VLP conditions were subtracted from the S-positive VLP 
conditions. For data depiction, the cell-associated Rluc signal in the spike-less (No S) 
VLP conditions were set to zero for each biological repeat of the experiment. 
VLP Entry Assay 
VLPs used for entry assays were prepared by cotranfection with CoV S, E 
(envelope), M (matrix) and DSP8-11-N encoding plasmids.  The resulting VLPs contained 
DSP8-11 fragments in their interiors.  To quantify VLP-associated DSP8-11 levels, VLPs 
were mixed with excess DSP1-7, in Passive Lysis Buffer, for 30 min at 37oC, to allow for 
DSP1-7-DSP8-11 complementation.  The excess DSP1-7 was obtained from HEK293 cells 
overexpressing DSP1-7 fragments.  Following post-lysis complementation, samples were 
introduced into opaque microplate wells and luminescence readings used to infer DSP8-





VLPs in FBS-free DMEM were inoculated onto target cells that were transfected 
2 days earlier with pDSP1-7.  Indicated experiments included cotransfection of target 
cells with pDSP1-7  and pCAGGS-TMPRSS2FLAG (212).  For VLP inoculations, input 
multiplicities were normalized to VLP DSP8-11 levels.  After 6 h at 37°C, cells were 
rinsed three times with PBS, dissolved into Passive Lysis Buffer and Rluc activities 
quantified. 
Virus and Pseudovirus Particle Entry Assays 
Virus particles were incubated with cells, either with or without prior 
neuraminidase treatments, for 2 h at 4°C.  Cells were then rinsed three times with PBS 
and replenished with FBS-containing DMEM / MEM.  After 16 h at 37°C, cells were 
dissolved in lysis buffer [25 mM Tris-phosphate (pH 7.8), 2 mM DTT, 2mM 1,2-
diaminocyclohexane-N,N,N’-tetraacetic acid, 10% (vol/vol) glycerol, 1% Triton X-100] 
and Fluc levels quantified with Fluc substrate [1 mM D-luciferin, 3 mM ATP, 15 mM 
MgSO4·H2O, 30 mM Hepes (pH 7.8)] and a Veritas microplate luminometer. 
For HIVpps entry, particles were inoculated onto target cells, and viral entry was 
allowed for 18 h. Unbound particles were rinsed away before intracellular Fluc levels 
were quantified. 
Cell-cell Fusion Assay 
Effector and target cells were prepared by introducing expression plasmids, 
using the PEI transfection method.  Effector cells were co-transfected with pDSP1-7 and 
the indicated S-expressing plasmids.  S-expressing plasmids included pcDNA3.1-229E 





Control effector cells received pDSP1-7 and empty vector plasmids.  Target cells were 
co-transfected with pDSP8-11   and the indicated S receptor-expressing plasmids.  These 
included pCMV6-Entry-hDPP4FLAG and pcDNA3.1-hAPN (accession # M22324; 
obtained from Dr. Fang Li).  Indicated experiments included additional cotransfection of 
target cells with pCAGGS-TMPRSS2FLAG.     
At 6 hrs post-transfection, effector and target cells were rinsed with PBS, lifted 
with 0.05% trypsin, and mixed at 1:1 ratios.  The co-cultures were incubated for 2 to 18 
h at 37°C. Fused cells were visualized microscopically as GFP+ cells, and extents of 
cell-cell fusion were quantified as Rluc activities present in PLB cell lysates.  Samples 
were chilled and maintained at 4°C during PLB with PLB and Rluc quantifications to 
eliminate DSP post-lysis complementation. 
To detect JHM-CoV cell-to-cell spread, DBT cell were inoculated with JHM-CoV 
at moi = 10 for 5 h. Cells were rinsed extensively to remove excess viruses. Cells were 
lifted via trypsinization, and were added to target HeLa / HeLa-mCEACAM cells, in the 
presence of titrated levels of NA, and the live-cell Rluc substrate, EnduRen (promega, 
E6482). The target cells were co-cultures of DSP1-7 and DSP8-11- expressing cells.  
JHM-CoV infected cells fuse with multiple target cells, which enables DSP1-7:DSP8-11 
complementation into active Rluc, which was quantified. 
Fc Constructs 
pCEP4-mCEACAM-Fc was constructed previously (146).  Splice overlap 
extension PCR was used to insert unique MreI and thrombin cleavage site and a 





IgG1 splice donor site.  Using this modified construct, the mCEACAM coding region was 
removed and replaced with MERS-S1 (codons 1-751), MERS-S1A (codons 1-357), 
MERS S1A (N222D), and MERS S1B (codons 1-24 from hCD5 signal followed by 
MERS S codons 358-588).  
HEK293T cells were transfected using the PEI method and then incubated in 
FBS-free DMEM containing 2% (wt/vol) Cell Boost 5 (Hyclone). Supernatants were 
collected on days 4 and 7, and clarified by sequential centrifugation (300xg, 4°C, 10 
min; 4500xg, 4°C, 10 min).  The Fc-tagged proteins were then purified using HiTrap 
Protein A High Performance Columns (GE Healthcare) according to the manufacturer’s 
instruction. The resulting purified proteins were quantified spectrophotometrically, 
verified using western blotting with a known quantity of human IgG as the control, and 
stored at -20°C until use. 
Fluorescence Staining 
 HeLa or HeLa-mCEACAM cells were pretreated with NA at 0, 0.5, 1, or 2 U/ml at 
37°C. Following rinses, cell surface sialate levels were assessed by co-incubating cells 
with AlexaFluor 647-conjugated wheat germ agglutinin (WGA-Alexa647, Molecular 
Probes) for 1 h at 4°C. Following fixation and Hoechst staining, immunofluorescence 
was assessed using confocal microscopy. 
Western Blotting 
Proteins in SDS solubilizer [0.0625 M Tris·HCl (pH 6.8), 10% glycerol, 0.01% 
bromophenol blue, 2% (wt/vol) SDS, +/- 2% 2-mercaptoethanol] were heated at 95°C 





nitrocellulose membranes (Bio-Rad), and incubated with mouse monoclonal anti-MHV-
HR2 10G (obtained from Fumihiro Taguchi, Nippon Veterinary and Life Sciences, 
Tokyo, Japan), mouse anti-C9 (EMD MIlliopore), mouse monoclonal anti-MHV HE, 
clone 5A11, goat anti-human IgG (sc-2453, Santa Cruz Biotechnologies), or rabbit anti-
FLAG (Sigma F7425). After incubation with appropriate HRP-tagged secondary 
antibodies and chemiluminescent substrate (Thermo Fisher), the blots were imaged and 
processed with a FlourChem E (Protein Simple).   
Microscopy and Image Acquisition 
Live and formalin-fixed cell images were captured in a z series on an electron 
multiplied charge coupled device digital camera (EMCCDCascade 2; photometrics) and 
deconvolved using SoftWoRx. Identical conditions were applied to all acquisitions. 
Deconvolved images were analyzed by an identical algorithm in Imaris 8.3.1 (Bitplane). 
Statistical Analysis 
Unless stated otherwise, all experiments were repeated independently at least 
three times. Each data point graphed represents the mean of an independent repeat 
(N), generated from three or four technical repetitions (n = 3 or 4).  Statistical 
comparisons were made by unpaired Student’s t test. Error bars indicate the standard 







SECTION 1: CoV S, Receptor, and Protease Form the Basic Elements for 
Membrane Fusion 
CoV Entry is Spike-directed, Receptor-facilitated, and Protease-triggered 
As previously mentioned, the major determinant for CoV permissibility is at the 
initial step of viral entry (99, 100). CoVs evolved to utilize a single viral surface 
glycoprotein, S, for viral entry and to establish de novo infections. Biologically, CoV S 
has two main functions: First, S is responsible for locating CoV particles to permissive 
target cells. Second, once tethered, S is also responsible for the delivery of CoV 
genome into the target cell cytoplasm, through the fusion between the viral envelope 
and the target membrane. The mechanistic details entailed within and between these 
two steps have been best characterized in the context of a virion and a cell (Figure 8A). 
To infect a cell, CoVs require S proteins to engage with receptors (sialoside or protein). 
This interaction putatively induces S to go through a structural transition that promotes 
the subsequent proteolytic cleavages. Cellular proteases, soluble or membrane-
associated, cleaves to separate and enable the membrane fusion machinery. These 
cleavages trigger further S conformational changes that involve connecting and fusing 







Figure 8. The Role of S, Protein Receptor, and Protease During CoV Entry. (A) To 
infect a cell, CoV requires S : receptor interactions, Protease cleavages of S, and S-
mediated membrane fusion mechanisms. (B) HEK293T cells were inoculated with HIV-
pps bearing either MERS S or VSVG. Target cells overexpressed MERS protein hDPP4 
receptor either with or without hTMPRSS2. After inoculation the excess virions were 
rinsed away. The inoculated cell culture was incubated overnight for Fluc reporter 
expression. The activity of Fluc, whose coding sequence is within the HIV-core plasmid, 







To validate the current knowledge regarding CoV virus-cell entry, we co-
transfected HEK293T cells with expression plasmids for HIV-core-Fluc, MERS S or 
VSVG and harvested cell supernatant 2 d post-transfection. Clarified supernatant, which 
contained HIV pseudoparticles (HIVpp) bearing MERS S or VSVG, was laid onto 
HEK293T cells overexpressing the protein receptor hDPP4 and/or the transmembrane 
protease hTMPRSS2. The experiment was terminated at 48 hpi and viral entry was 
inferred by quantifying Fluc activities, whose open reading frame (ORF) is within the 
HIV-core sequences. In agreement with the field, MERS S-directed viral entry signal 
was elevated ~20-fold with sufficient level of hDPP4 (Figure 8B). Viral entry was further 
increased ~50-fold when target cell surface protease, hTMPRSS2, was enriched. This 
entry characteristic is MERS S-specific, because viral entry mediated by VSVG, which 
uses LDLRs as receptors and endocytic protonation as the fusion trigger (80, 164), 
were consistent regardless of hDPP4 and hTMPRSS2 expression levels (Figure 8B). 
FRET-based In Vitro Characterization of Viral Fusion 
The most common ways to characterize viral entry is to quantify certain effects 
that take place downstream of viral entry, such as reporter expressions (e.g. luciferase, 
GFP), specific target cell factor alterations (e.g. IFN), or cell death (e.g. plaques). The 
HIVpp-based assay we used in figure 8B is one of them. While these traditional ways to 
detect viral entry are efficient, they do have a few limitations. First, their readouts are 
not the actual viral entry event, but derivatives a few steps downstream of it, which 
potentially adds many other variables. Second, viral fusion targets in these systems are 





the entry process. Third, cell maintenance have specific requirements, which limit the 
extent to which viral fusion environments can be manipulated. In order to characterize 
CoV viral entry through direct detection of membrane fusion, as well as to have flexible 
manipulations of potential factors for this fusion, we developed a FRET-based in vitro 
viral membrane fusion system to characterize CoV viral fusion. It was demonstrated that 
fusing the first 15 amino acid sequences of c-Src protein (S15) to certain fluorescent 
proteins would, via the post-translational modification of myristoylation, anchor these 
proteins to cellular membranes (220). Furthermore, these membrane-associated 
fluorescent proteins (S15-GFP or S15-mCherry) are readily incorporated into HIV-1 
virions (213), enabling the tracking of viral particles (Figure 9A). We hypothesized that, 
if CoV S, receptor, and protease are the minimum requirement for membrane fusion, 
then a mixture of MERS S-bearing HIVpps, hDPP4-bearing HIVpps, and trypsin, should 
cause the two particles fusing together. Furthermore, if the S-bearing particle contained 
S15-GFP, and the receptor-bearing particle contained S15-mCherry, then fusion could 
be quantified by detecting the FRET activity induced by the two fluorescent proteins 
being within close proximities of each other (Figure 9B). 
MERS-CoV S, hDPP4, S15-GFP, and S15-mCherry are Incorporated into HIV pps 
The viability of the proposed in vitro viral fusion system requires the correct 
incorporations of MERS S, hDPP4, S15-GFP, and S15-mCherry into HIV pps. To test 
this, HIVpps were produced from HEK293T cells expressing either MERS S and S15-
GFP, or hDPP4 and S15-mCherry. HIVpp-containing cell supernatants were collected 







Figure 9. FRET-based In Vitro Characterization of Viral Fusion. (A) Schematic for 
HIV pps incorporating GFP that is N-terminally fused to the first 15 amino acid 
sequences of c-Src protein (S15), followed by a linker sequence. S15 is subjected to 
myristoylation, and together with internal positive charges, locates GFP to cell 
membrane, where it can be incorporated into the budding HIV pps. (B) Schematic for in 
vitro fusion system. Using the methodology from panel A, HIV pps could be produced to 
incorporation MERS S proteins, hDPP4, S15-GFP, and S15-mCherry. If S15-GFP and 
S15-mCherry are incorporated into MERS S and hDPP4 virions, respectively, then only 
after inter-particle membrane fusion can the two fluorescent proteins come within ~10 






To assess the incorporation of MERS S and hDPP4 onto HIVpps, particles were 
concentrated down via ultrafiltration, and 100x samples were used for immunoblotting. 
MERS S detection was mediated by antibody against C9-tag, which was fused to the C-
terminus of the S protein. hDPP4 was detected by antibody against flag-tag, which was 
added to the C-terminus of hDPP4 protein. Both proteins were readily secreted with 
HIVpps (Figure 10A and B). To test the secretion of S15-GFP and S15-mCherry, we 
pelleted MERS S-HIVpps and hDPP4-HIVpps onto separate coverslips, utilizing an 
established spinoculation method (197, 213). After fixation, coverslips were evaluated 
using fluorescent microscopy. As expected, GFP+ particles were detected in the MERS 
S condition, and mCherry+ particles were detected in the hDPP4 condition (Figure 10C). 
We further reasoned that, if native, functional, MERS S and S15-GFP, as well as 
hDPP4 and S15-mCherry, were co-incorporated onto their respective HIVpps, then 
these particles should bind to each other upon mixing, which could be detected as GFP-
mCherry co-localization. To test this, these two HIVpp populations were mixed one-to-
one before spinoculation, and visualized via fluorescent microscopy. Remarkably, we 
observed a near-total co-localization between GFP+ and mCherry+ particles (Figure 
10D), suggesting that all components were co-secreted as expected. 
Virion Fusion Minimally Requires CoV S, Protein Receptor, and Protease 
We aimed to test whether CoV S, protein receptor, and protease are the minimal 






Figure 10. HIV pps Incorporate MERS S, hDPP4, S15-GFP, and S15-mCherry. (A) 
Western blot detection of MERS-S-C9 protein incorporation into HIV pps. HIV pps were 
collected at 48 h post-transfection, and concentrated/purified via ultrafiltration. The 
protein content of HIV pps bearing either MERS S or No S (Bald) were resolved via 
SDS-PAGE and blotted onto nitrocellulose membrane. The presence of MERS S was 
detected by mouse α-C9. (B) Wester blot detection of hDPP4-FLAG. Procedures were 
as described in panel A. hDPP4 presence was detected by rabbit α-FLAG. (C) HIV pps 
were generated by the co-transfection of plasmids for either S15-GFP and MERS S, or 
S15-mCherry and hDPP4. Particles were spinoculated onto glass coverslips and their 
fluorescence were assessed after fixation. (D) MERS-S-S15-GFP pps were mixed with 
hDPP4-S15-mCherry pps. Mixture was spinoculated and particle fluorescence and 





Trypsin has been demonstrated to be an adequate triggering protease for CoV S-
mediated membrane fusions (167, 170). To determine the effective trypsin dose needed 
for the in vitro fusion system, we incubated MERS-S-HIVpps with titrated concentrations 
of trypsin for 30 min. The S proteins on these virions were then subjected to 
immunoblotting, because trypsin-induced S cleavage patterns correlated well with 
infectivity (167). Because we saw a dose-dependent gradual decrease of S oligomer 
upon trypsin treatment, and a dramatic reduction of intact S proteins upon high trypsin 
presence (Figure 11A), we chose an intermediate trypsin dose of 5 µg/ml to trigger in 
vitro membrane fusions in our subsequent experiments. Incidentally, 5 µg/ml of trypsin 
is also within the effective dose window determined previously for MERS-S-HIVpps 
(167). 
After deciding on using trypsin as the triggering protease for MERS S-induced in 
vitro fusion, we next searched for a fusion inhibitory agent. Soluble HR2 peptides were 
developed to be CoV specific fusion inhibitors (195, 221–223), and their effectiveness 
against MERS S has been well characterized (174). Because HR2 peptides are derived 
from an S protein C-terminal α-helix region whose interaction with the HR1 region is 
required for the S protein fold-back action that pulls the viral and target membrane into 
close proximity, HR2 peptides, mechanistically, inhibit S-mediated membrane fusion at 
the very last stage. Because its mechanism of action is at a step subsequent to receptor 






Figure 11. Functional Assessment of Factors Used in In Vitro Fusion Assay. (A) 
Western blot detection of dose-dependent MERS S proteolysis. MERS S pps were 
incubated with a titration of trypsin for 30 min at 37°C. Following trypsin inhibition, 
samples were resolved and S cleavage products detected by mouse α-C9. (B) S15-
GFP+ pps were mixed with S15-mCherry+ pps and their % co-localization was assessed 
via fluorescent microscopy. Specific conditions are as indicated. In “Bald” conditions, no 






Because variations in the co-localization between GFP+ and mCherry+ particles, 
facilitated by the S : hDPP4 interactions, could greatly impact the efficiency of the 
downstream viral fusion event, we next tested whether trypsin or HR2 peptides had any 
unexpected effects on S : hDPP4 interactions. To this end, MERS-S-GFP pps were 
mixed with hDPP4-mCherry pps either with or without trypsin or HR2 peptides, and the 
percent co-localization of GFP+ and mCherry+ particles were microscopically quantified. 
As a negative control, (Bald)-GFP particles were mixed with (Bald)-mCherry particles. 
As expected, the S : hDPP4 interaction resulted in the co-localization of the majority of 
the particles (Figure 11B). We noted that the addition of neither trypsin nor HR2 
peptides had affected this co-localization. This co-localization, however, was reduced by 
soluble S1 subunits (S1-Fc) of the S protein in a dose-dependent manner. The co-
localization was further brought down to the level of the negative control (Bald x Bald) in 
the absence of hDPP4 (S x Bald). Both of these observations suggested that particle 
co-localization is a specific reflection of S : hDPP4 interactions. MERS S proteins have 
been found to bind to sialic acid moieties on the target cell membrane (126), but this 
interaction was evidently not sufficient to co-localize particles. We reasoned that our in 
vitro particle binding system might not be ideal for MERS S : sialic acid interactions, 
either because S proteins are not appropriately-assembled on HIVpps, as demonstrated 
that correct oligomerization of MERS S is required for detectable sialoside-interactions 
(126), or the sialoside moieties on HIVpps are insufficient for the avidity-dependent 
MERS S interactions. Additionally, the affinity between MERS S and sialic acids might 





HAs resulted in a detectable, albeit reduced particle co-localization (IAV HA x Bald) 
(Figure 11B). Taken together, these results suggest that, in our system, particle co-
localization is a direct result of MERS S : hDPP4 interaction, and neither trypsin nor 
HR2 peptides affects this interaction. 
To induce in vitro particle fusion, MERS-S-GFP pps were incubated with hDPP4-
mCherry pps. Subsequently, trypsin was added either with or without HR2 peptides. 
Trypsin activity was inhibited 30 min later by the addition of soybean trypsin inhibitor. 
The mixture was then spinoculated onto a coverslip, fixed, and GFP+ mCherry+ 
particles, including particles either merely bound together or fused together, were 
analyzed for FRET induction (Figure 12). 
 
Figure 12. In Vitro Viral Membrane Fusion Assay. MERS-S-S15-GFP pps were 
incubated with hDPP4-S15-mCherry pps for 30min at 37°C. Trypsin either with or 
without HR2 peptides were added into the mixture and further incubated for 30min 
before inhibitor was added to neutralize trypsin activity. Particles in the mixture was 
subsequently spinoculated onto a glass coverslip. After fixation, FRET activity was 
measured for GFP+ mCherry+ puncta. The representative micrograph was a result from 





To detect FRET induction, we photobleached the FRET acceptor (mCherry), and 
quantified the fluorescence change in the FRET donor (GFP). If particles were bound 
but not fused, the distance between GFP and mCherry would be too great (>10 nm) for 
energy transfer. In this case, photobleaching mCherry would result in no GFP 
fluorescence change. If particles were fused, mCherry can come close enough (<10 
nm) to GFP and absorb some of the GFP fluorescence. In this case, photobleaching 
mCherry would result in a net gain of detectable GFP signals (Figure 13A). To quantify 
relative FRET induction, we first set the GFP emission pre-bleach to 1. In the absence 
of FRET, the post-bleach GFP emissions should be evenly distributed around 1. In 
other words, the % to the right of 1 minus the % to the left of 1 equals zero. Therefore, if 
FRET occurs, the resulting value should be greater than zero (Figure 13A). To define 
the experimental FRET detection window, we first tested the controls. As a positive 
FRET control, we made Bald pps that incorporated both S15-GFP and S15-mCherry. 
As expected, we detected high relative FRET in these particles. As a negative FRET 
control, we mixed MERS-S-GFP pps with hDPP4-mCherry pps without trypsin, and 
found a negligible FRET induction (Figure 13B). 
Using FRET as a direct readout for S-induced membrane fusion, we found that 
the addition of trypsin alone was sufficient to induce FRET among the co-localizing 
GFP+ mCherry+ particles (Figure 14A). It is known that HR2 peptides block CoV S-
mediation fusions by physically interfering directly with the fusion machinery within S2 




































Figure 13. FRET Induction Reflects S15-GFP – S15-mCherry Compartmentalization. (A) 
Schematic for FRET quantification. When GFP is in separate membrane compartments from 
mCherry, their distance is too great so that mCherry photobleaching would not impact GFP 
emission. Conversely, when GFP and mCherry share a membrane compartment, their distance 
can be within 10 nm, so that mCherry photobleaching would disable FRET, and resulted in an 
apparent gain of GFP emission. If we set the GFP emission before mCherry photobleaching to 
1.0, then when there is no FRET, GFP emission should stay constant, normally-distributed 
around relative emission of 1.0. When FRET is present, the puncta GFP emission should be 
greater than 1.0. In other words, if % Right - % left = 0, then there is no FRET. If % Right - % 
Left > 0, then FRET is induced. Hypothetical data are depicted. (B) As a proof-of-concept, as 
well as assessing control conditions, FRET induction was calculated, as described in panel A, 
for conditions where S15-GFP and S15-mCherry were co-incorporated into pps, and S15-GFP 
pps were merely bound to S15-mCherry pps via S : hDPP4 interactions. For the former, % Right 
- % Left = 96.8, suggesting strong FRET induction. For the latter, % Right - % Left = 6, implying 






































Figure 14. In Vitro Fusion Assesses the Sufficiency of Proteases in S-mediated 
Membrane Fusion. (A) The assessment of the effect of exogenous trypsin on MERS S-
mediated in vitro membrane fusion. Experimental procedure was as described in Figure 12. 
Each data point represents the average of an independent experiment, where >300 
GFP+mCherry+ puncta were analyzed.  Error bars represent standard error (SE) from the mean.  
Statistically significant deviations from MERS S pps mixed with hDPP4 pps without additives (S 
x hDPP4) were assessed by unpaired Student’s t test; ns, not significant. * p<0.05; ** p<0.01; 
*** p<0.001; **** p<0.0001. (B) Western blot detection of hTMPRSS2-FLAG. hDPP4-
hTMPRSS2-S15-mCherry pps were produced by adding the expression plasmid for 
hTMPRSS2-FLAG during HIV pp production stage. Samples were processed as described in 
Figure 10B. (C) The assessment of the effect of hTMPRSS2 on MERS S-mediated in vitro 
membrane fusion. Experimental procedure was identical to panel A, only that trypsin was not 
added to the hTMPRSS2 condition. Data processing and statistical analysis were done as 





Therefore, the potent inhibitory effect of HR2 peptides observed here validated that the 
detected FRET was due to the induction of MERS S : hDPP4 – dependent membrane 
fusions, and not alternative mechanisms, such as proteolysis-induced membrane 
damages. Furthermore, because MERS-CoVs have been identified to preferentially use 
cell surface TTSPs for entry (138, 167, 174), we assessed the role of hTMPRSS2 on 
triggering S-mediated membrane fusion. To this end, HEK293T cells producing hDPP4-
HIVpps were co-transfected with hTMPRSS2 plasmid, which resulted in co-
incorporation of hDPP4 and hTMPRSS2 onto HIV pps (Figure 14B). When hDPP4-
hTMPRSS2-HIVpps were used in the in vitro fusion system, we observed a significant 
FRET elevation comparing to hDPP4-HIVpps, comparable to the induction level of 
exogenous trypsin (Figure 14C). Taken together, we concluded that MERS S requires 
only its protein receptor and the triggering protease to induce membrane fusion. The 
triggering proteases include trypsin and a more biologically relevant hTMPRSS2. 
Furthermore, we established this FRET-based in vitro fusion assay using MERS S as a 
proof-of-concept, but we believe this system can be readily adapted to other fusion 
contexts, given that the fusogen and receptor can be enriched on the pseudoparticles. 
SECTION 2: MHV-JHM Spike Utilizes Host Sialosides During Viral Entry and 
Spread 
MHV-JHM CoV Agglutinates RBCs 
It was proposed that CoV S domain As evolved from carbohydrate-binding 
galectins (118). This proposal is supported by the findings that these domain As are 





106, 113, 125). The domain A of MHVs appears to be an evolutionary divergent, where 
they have evolved protein (mCECACAM) binding determinants on their galectin-like 
domain As (104, 121). We considered it likely that some MHV CoV strains also retain 
sialic acid binding competence, making these domain As evolutionary intermediates 
(Figure 4A). This presumption came from studies of the JHM-CoV strain of MHV. JHM-
CoV can infect mCEACAM knockout mice (129), and can mediate cell-cell fusion of 
several mCEACAM-negative cell types (143, 146, 196, 197, 224, 225).  Amongst the 
CoVs, only the JHM-CoV strain has these documented activities that are apparently 
independent of a protein receptor, making it a sensible virus to use in addressing the 
hypothesis that sialate- and protein receptor-binding activities coexist on CoV S domain 
As.   
We were first interested in determining whether the S proteins on JHM-CoV 
interacts with host sialic acids. To narrow our interpretation on any potential results, we 
needed to eliminate the effect of other possible sialic acid-binding agents on the JHM 
virion. JHM is one of a few MHVs that can express and incorporate the non-major 
structural protein, hemagglutinin-esterase (HE), into virus particles (226, 227). CoV HEs 
enzymatically cleave the acetyl group on sialic acids, and hence their putative biological 
role is to destroy RBD-sialic acid interactions to facilitate viral release, analogous to the 
role of neuraminidase (NA) during IAV release, as it was documented for HKU1-CoV 
(228). As expected, CoV HEs are capable of binding to host sialic acids (228, 229). It 
has also been documented that JHM-CoV isolates can vary greatly in their HE 






Figure 15. MHV-JHM CoV Agglutinates RBCs. (A) Western blot detection of virion 
hemagglutinin esterase (HE) proteins. Purified recombinant JHM-CoV particles, 
normalized based on viral RNA abundance, were subjected to western immunoblotting.  
Virion HE proteins were detected using mouse α-MHV-HE 5A11. (B) Western blot 
detection of virion S proteins. Purified A59-CoV and JHMHE--CoV were subjected to 
western immunoblotting.  Virion spike (S) proteins were detected using mouse α-MHV-S 
(10G). The relative band intensities were used to normalize viral input in the 
hemagglutination assays. (C) Hemagglutination assay. JHMHE--CoV, A59-CoV, or IAV 
pps were serially 2-fold diluted from left to right, placed into V-bottom wells, and 
incubated for 2 h at 4°C.  Human adult erythrocytes were then added, to a final 0.25% 
v/v. Hemagglutination was scored (positivity highlighted in blue circles) after 2 to 12 h at 





Therefore, we selected a JHM-CoV isolate that lacks HE expression (Figure 15A), so 
that any observable sialic acid interactions are likely attributed to S proteins. 
Sialic acid-binding viruses will agglutinate erythrocytes.  To determine whether 
sialic acid binding has a critical role in JHM-CoV entry, we evaluated hemagglutination 
of human erythrocytes. Influenza A virus hemagglutinin (HA)-bearing pseudoparticles 
(IAVpps) were used as a positive control. As a comparison, another MHV strain, A59-
CoV, was used, whose S protein has not been found to interact with sialic acids (125). 
Because JHM and A59 vary in their S protein stabilities, we normalized particle input 
based on their spike contents (Figure 15B). Viral particles, or mock, were placed in 2-
fold dilutions across the V-bottom plate and incubated for 2 h. Subsequently, human 
erythrocytes were mixed in and hemagglutination titers were scored after 2-12 h. 
Intriguingly, JHMHE--CoV virus particles agglutinated human erythrocytes, while the 
related A59-CoV strain did not (Figure 15C), even at particle-associated S protein input 
levels slightly exceeding the corresponding JHMHE—CoV. These findings suggested that 
JHM uniquely engages host sialic acids, and this interaction is likely facilitated by its S 
protein. 
JHM Spike Protein Engages Sialosides on Target Cells 
To validate the presumed JHM virus spike – host cell sialic acid interaction, we 
needed a system where we could compare sialic acid interactions down to a single 
variable, the S protein. The feasibility of any potential system was further complicated 
by the finding that weak sialic acid interactions are not detectable unless the S proteins 





elicited no detectable readout, sialic acid interactions were readily detected when the 
domain As of MERS-CoV and HKU1-CoV were oligomerized onto nanoparticles (125, 
126). Additionally, we noted that the aforementioned in vitro fusion system (see 
SECTION 1) was likely not suitable to detect weak sialic acid interactions (Figure 11B). 
Because we expected a weak JHM S-sialic acid interaction, we developed an 
analogous system with virus-like particles (VLPs), where S proteins are oligomerized 
similarly to the authentic virus. It has been shown that CoV major structural proteins 
self-assemble into VLPs (1, 2, 4, 5, 230). We developed a MHV-based VLP system, in 
which VLPs contained reporter proteins that can be tracked during virus-cell binding and 
entry (Figure 16A). To produce MHV-VLPs, HEK293T cells were co-transfected with the 
expression plasmids for the structural genes E, M, N, and either S or vector control (1, 
3, 4). The N genes plasmids were modified by in-frame fusion with dual-split protein 
(DSP) encoding sequences. While devoid of signals in separation, when DSP1-7 
encounters DSP8-11, the two molecules complement to form a complete Renilla 
luciferase (Rluc) and green fluorescent protein (GFP) chimeric reporter (217, 218). 
Therefore, the incorporation of DSP1-7-N and DSP8-11-N proteins into VLPs allowed for 
the release of particles that were intrinsically Rluc- and GFP-positive. These MHV-VLPs 
were further purified from cellular debris through a 20% sucrose cushion. 
Next we needed to analyze the VLPs, and test whether they resembled authentic 
MHVs, specifically, whether the S proteins were incorporated similar to the authentic 
virus. To this end, we analyzed the state of the incorporated JHM S proteins on these 






Figure 16. MHV-JHM VLPs Resemble Authentic Viruses. (A) Schematic for VLP 
production and purification. Supernatants containing MHV-CoV VLPs were collected 
from HEK293T cells expressing viral structural genes S, E, M, and DSP1-7-N / DSP8-11-
N. VLPs were purified through 20% sucrose cushions and quantified by assessing Rluc 
levels. Both DSP reporter halves were used to generate VLPs that contained internal 
Rluc and GFP. (B) Western blot detection of JHM S proteins in JHM pp (left), JHM VLP 
(middle), and authentic JHM-CoV (right). Particle-incorporated spike (S) proteins were 
detected using mouse α-MHV-S (10G), which binds to the C-terminus of the S2 subunit. 
The peptide molecular weight associated with the S2 subunit is an indicator of whether 
the S protein has been uncleaved at S1/S2 site (~200 kDa.), cleaved at S1/S2 (~110 
kDa), or degraded beyond a functional size (~40 kDa.). Particles were produced in 
parallel and purified identically. 
 
We noted that MHV VLPs incorporated intact JHM spike proteins at levels that were 
similar to authentic viruses (JHM CoV), indicated by the prominent S2 band at ~100 
kDa. This was in contrast to JHM spikes that were incorporated into VSV-based 
pseudoparticles (JHM pp), a widely utilized approach to assess CoV S functions, where 
most of which were degraded, as indicated by a prominent S2 band at ~40 kDa (Figure 





structures, at least with respect to spike stability and particle incorporation. As spike 
stability and multivalent presentation is frequently  required to detect sialate interactions 
(125, 126), we considered the VLPs to be well-suited to reflect S-sialioside interactions 
of the authentic virus. Additionally, VLPs are equally produced either with or without 
incorporated S proteins (2), making spike-less (No S) VLPS the ideal control for any 
non-S-dependent signals, making it possible to quantify S protein – dependent virus-cell 
binding processes. Furthermore, we reasoned that, with the spike-less VLP as 
background control, we could minimize / avoid cell-rinsing and be well-equipped to 
detect weak viral associations with target cells. 
To this end, we first generated VLPs either with or without JHM or A59 S 
proteins. Via immunoblotting, we noted that the S protein levels on the A59 VLPs 
exceeded those of JHM VLPs (Figure 17A), even though the VLP quantities were 
normalized based on their internal Rluc signals (Figure 17B). This was expected, since 
it was known that A59 S is more stable than JHM S (147, 192). Interestingly, when 
these VLPs were applied to mCEACAM-negative HeLa cells at equivalent Rluc 
multiplicities, in agreement with the hemagglutinating effects of the viruses, the JHM S 
proteins increased VLP : HeLa cell binding above background levels (No S, subtracted 
from each data point), while the A59 S proteins did not (Figure 17C).  
To assess whether the observed, JHM S-facilitated, VLP-binding is mediated by 
target cell sialiosides, we compared VLP-binding to cells either with intact sialosides or 






Figure 17. JHM S Protein Engages Sialosides on Target Cells. (A) Western blot 
detection of A59 and JHM S proteins in VLPs. Particle-incorporated spike (S) proteins 
were detected using mouse α-MHV-S (10G). (B) Bald (No S), A59 or JHM S-bearing 
VLPs contained equal internal Rluc activities. (C) VLP binding assay. HeLa cells were 
formalin-fixed, rinsed, and incubated for 2h at 4°C with VLPs bearing A59 or JHM S.  
Rluc input multiplicities were equal for all VLP inoculations.  Media were removed, cells 
lysed, and cell-associated Rluc activities quantified. Data are presented after 
subtracting background (“No S”) Rluc+ VLP levels, with each data point representing 
averages from independent experiments (N = 8 (A59) and 7 (JHM); n = 4 technical 
replicates per experiment).  Error bars present standard error (SE) from the mean.  
Statistically significant deviations from background (“No S”) binding were assessed by 
unpaired Student’s t test; ns, not significant. * p<0.05; ** p<0.01; *** p<0.001; **** 
p<0.0001.  (D) HeLa or HeLa-mCEACAM cells were fixed and treated with vehicle 
(PBS) or neuraminidase (NA) for 3 h at 37°C.  JHM-CoV VLPs were then added for 2h 
at 4°C, cell-associated Rluc activities quantified, and data presented after subtracting 
background (“No S”) Rluc+ VLP levels.  Error bars present standard error (SE) from the 
mean.   Statistically significant deviations were assessed by unpaired Student’s t test; 





Notably, the JHM VLPs did not bind to HeLa cells that were pre-treated with NA (Figure 
17D, left), suggesting that the observed VLP binding was dependent on cellular sialic 
acids, which serves as an attachment factor for JHM S. 
This result appeared to contradict with the general belief that the principle 
receptor, mCEACAM in the case of JHM, is responsible for viral attachment. Therefore, 
we tested the role of mCEACAM in JHM VLP binding. Surprisingly, VLP binding to cells 
was not increased by the expression of the MHV protein receptor mCEACAM in HeLa 
cells, and more importantly, all observed VLP-bindings to mCEACAM-expressing HeLa 
cells remain completely sensitive to the pre-removal of sialic acids by NA (Figure 17D, 
right). Together these data suggest that, during MHV-JHM infection, the initial viral 
attachment process is mediated by S protein:sialic acid interactions, and not by the 
protein receptor mCEACAM. 
JHM Spike Requires Protein Receptor for Membrane Fusion During Viral Entry 
Since our VLP-binding results suggested that the protein receptor, mCEACAM, is 
not the major contributor to viral binding (Figure 17D, right), we wanted to test its 
involvement during viral entry. In addition, since we have identified the prominent role of 
sialic acids on JHM viral binding, we next aimed to identify the biological importance of 
the JHM spike-sialate interaction. We reasoned that this interaction could either be 
sufficient for viral entry or may instead be an early step preceding viral engagement with 
protein (mCEACAM) receptors. We modified our VLP system to turn it from a binding 
assay to an entry assay. Instead of transfecting in plasmids for both DSP1-7-N and 





plasmid was included. This produced DSP8-11-positive, but Rluc- and GFP-negative 
VLPs. To quantify the relative numbers of these DSP8-11-positive VLPs, purified VLP 
samples were lysed, and subsequently mixed with cell lysates containing a surplus of 
DSP1-7 proteins. The Rluc signals generated from the post-lysis complementation of 
DSPs correlated with the number of VLPs supplied. To assess virus entry, we 
inoculated equal Rluc multiplicities of either spike-less or JHM S, DSP8-11-positive, VLPs 
onto DSP1-7-expressing target cells. Because the delivery of viral content into target cell 
cytoplasm is the direct outcome of viral entry, VLP entry into target cells could be 
measured by reporter complementation into active Rluc or GFP moieties (Figure 18A). 
S-dependent VLP entry events could be quantified by the elevated signals of JHM S 
VLPs over the background signals of spike-less VLPs. We compared VLP entries in 
HeLa and HeLa-mCEACAM cells and found that, even though JHM S : sialic acid, but 
not JHM S : mCEACAM, interactions facilitated significant VLP binding (Figure 17D, 
right), Rluc entry signals required mCEACAM presence (Figure 18B), measured by the 
~5-fold signal of JHM S VLPs over spike-less (So S) VLP background. The entry 
signals-to-background ratio were further elevated ~10-fold by the presence of 
TMPRSS2 (Figure 18B, hTMPRSS2), a known CoV fusion-triggering protease (99, 100, 
167, 170, 173, 182, 190, 194, 212, 231). This facilitating effect of TMPRSS2 supported 







Figure 18. Viral Binding to Sialosides Facilitates Protein Receptor-dependent 
Entry. (A) Schematic for VLP entry assay. VLPs containing DSP8-11-N were collected 
from transfected HEK293T cells, purified as described in Figure 16A, and inoculated 
onto target cells expressing DSP1-7.  Rluc signals arise after the fusion between VLP 
and target cell membranes, which enables the entry of DSP8-11-N into cells and 
subsequent complementation with DSP1-7. (B) HeLa target cells were transfected with 
DSP1-7, mCEACAM, and hTMPRSS2, as indicated.  At 2 d posttransfection, DSP8-11-
VLPs were collected, purified, and inoculated for 6 h at 37°C, then cells were lysed and 
Rluc activities measured. (C) The indicated target cells were pretreated with vehicle or 
NA for 2 h at 37°C, followed by inoculation with the indicated virus particles for 2 h at 
4°C. Unbound particles were removed by rinsing, and after 16 h at 37°C, cells were 
lysed and Fluc quantified to approximate viral entry. Data are presented as % viral 
entry, normalized to vehicle controls. Statistical analyses were performed as described 
in the Figure 17 legend. 
 
In conjunction with VLP binding data, these findings suggest that JHM-CoV cell entry is 
a multi-step process, with initial viral attachment facilitated by S : sialate interactions, 





Virus Binding to Sialic Acids Facilitates Protein Receptor-dependent Entry 
Using our VLP system, we have identified that JHM S binds to host sialic acids. 
We next aimed to determine whether this JHM S : sialic acids interaction has a 
detectable biological role. To this end, we tested whether NA pre-treatment of target 
cells affected protein-receptor-dependent JHM-CoV entry. Here authentic JHMHE--CoV 
particles were bound for 2h to different target cells, with or without prior cell exposures 
to NA. We included a small collection of different susceptible target cells: Mouse brain-
derived DBT cells were a common murine cell type used to grow MHVs (232), and we 
included this cell type to reflect common JHM entry conditions; Human HeLa cells were 
engineered to stably express the MHV murine protein receptor, mCEACAM (205). We 
included this cell type to represent a scenario where an originally non-permissive cell 
type were made susceptible by the protein receptor alone; Hamster-derived BHK cells 
were included to represent zoonotic cell types that, even though lacking mCEACAM, 
are nonetheless susceptible to JHM-CoV infections (197). Because host sialic acids are 
the receptors for IAV HA (233–235), IAVpps were used as a positive control for 
neuraminidase-mediated de-sialylation. VSVGpps were utilized as the negative control, 
because VSVG engages LDLR, and not sialic acids, to facilitate viral entry (164). After 
viral binding at 4°C, unbound particles were removed via extensive rinsing. Viral 
replication was continued for 18 h, before it was measured by quantifying viral Fluc 
reporter expression. Interestingly, NA pre-treatments universally decreased JHMHE--CoV 
entry into DBT (38%), HeLa-mCEACAM (38%), and BHK (54%) cells (Figure 18C). 





transduction, (Figure 18C). Partial resistance to IAV pp is best explained by incomplete 
removal of sialic acids by either the type or the dose of they neuraminidase used. We 
therefore infer that the partial NA resistance of JHMHE--CoV is similarly explained by 
incomplete sialic acid removal. On the other hand, the NA treatment deployed here 
likely did not cause any relevant secondary effects, because the transduction efficiency 
of VSVG pp was not hindered. These results support a model in which the sialic acid 
moieties on the cells from a wide range of animal species universally function as the 
attachment factor for the initial JHM virus binding to target cells, and this attachment 
aids the downstream protein receptor-mediated entry process. 
Sialic Acid Receptors Promote JHM Viral Spread without Requiring mCEACAM 
Protein Receptors 
To spread existing infections, CoVs utilize two distinct pathways. De novo CoV 
virions are produced from infected cells and released into the extracellular space, where 
they can be passively transported into close proximity to other naïve, but susceptible 
cells to initiate a new round of viral infection, via the process of canonical CoV entry. 
Alternatively, a CoV-infected cell can directly spread its infection into neighboring cells 
through the process of cell-cell fusion, or syncytia formation, mediated by CoV S 
proteins on the infected cell surface interacting with the cellular factors on the 
neighboring cell plasma membrane (99). For most CoV S proteins, cell-cell fusion 
requires the engagement with their principle receptors (194, 195, 212, 236). JHM S 
proteins can uniquely mediate syncytia in several conditions, even when mCEACAM 





mCEACAM-independent fusion activity was proposed to not require any receptor 
engagements. 
Because we have identified a weak JHM S : sialic acid interaction, we wanted to 
determine whether sialic acids operate independent of mCEACAM receptors in JHM 
cell-cell membrane fusion and syncytial development. Because our results suggested 
that we were inefficient at removing sialic acids from live cells (Figure 18C), we 
deployed an independent approach to assess the efficiency of live-cell de-sialylation. 
Wheat germ agglutinin (WGA) is known to bind various sialic acid species on the cell 
membrane (237). We incubated live HeLa or HeLa-mCEACAM cells with titrated doses 
of NA. Subsequently, cells were incubated with fluorescently-labeled WGA at 4°C, to 
eliminate the internalization of WGA. Confocal micrographs of the subsequently fixed 
cells revealed that, WGA-binding was reduced by NA in a dose-dependent manner 
(Figure 19A). WGA-binding, however, was not eliminated even at the highest NA dose 
tested. Cell morphology was not visibly altered at any of the NA doses tested, in 
agreement with the absence of detectable cytotoxic effects during VSVGpp transduction 
(Figure 18C). 
To determine the effect of target cell sialic acids on the JHM-CoV cell-to-cell 
spread, we utilized the DSP-complementation system and developed an assay to 
directly quantify JHM-CoV-induced viral expansion via cell-cell fusion. First, we 







Figure 19. JHM-CoV Cell-to-cell Spread Depends on Host Sialic Acids. (A) 
Immunofluorescence micrographs of target cells after NA treatments. HeLa or HeLa-mCEACAM 
cells were pretreated with NA at the indicated doses at 37°C. Following rinses, cell surface 
sialate levels were assessed by co-incubating cells with AlexaFluor 647-conjugated wheat germ 
agglutinin (WGA-Alexa647, Molecular Probes) at 4°C. Following fixation and Hoechst staining, 
images were captured by EMCCDCascade 2 camera and processed in Imaris 8.3.1. Images are 
representative of three technical repeats. (B) Schematic for JHM S protein-mediated cell-cell 
fusion measurements. JHM-CoV infected DBT cells (moi = 10; 5 hpi)  were added to target 
HeLa / HeLa-mCEACAM cells. The target cells were co-cultures of DSP1-7 and DSP8-11- 
expressing cells. JHM-CoV infected cells fuse with multiple target cells, which enables DSP1-
7:DSP8-11 complementation into active Rluc. (C and D) Quantification of Rluc over time in 
mCEACAM-negative (C) or mCEACAM-positive (D) target cells, in the presence of the indicated 
NA concentrations. Means (data points), SE (error bars), and the polynomial trendlines (R2 > 





At 5 hpi, we rinse away unbound particles, lift the DBT cells, and overlay them onto 
target cells consisting a one-to-one mix of DSP1-7-expressing cells and DSP8-11-
expressing cells. Overtime, if the cytoplasms of the DSP-expressing cells are bridged 
together by JHM S-mediated cell-cell fusions, then DSP1-7 would complement with 
DSP8-11, and Rluc and GFP signals would arise and be quantified (Figure 19B). Using a 
stable live-cell Rluc substrate, the development of active Rluc was measured over time. 
To analyze the role of target cell sialic acids on JHM S-mediated cell-cell fusion, a 
titration of neuraminidase doses were present throughout the time-course experiment. 
For JHM-CoV spread into mCEACAM-negative HeLa cells, the results (Figure 19C) 
revealed a NA dose-dependent reductions in JHM CoV-induced syncytia, where 
syncytia formation was completely eliminated at the highest 2 U/ml NA dose. This result 
suggested that JHM S-mediated, mCEACAM-independent cell-cell fusion heavily 
depends on target cell sialic acid moieties. Similar, but less pronounced reductions were 
observed in parallel cultures of mCEACAM-positive HeLa cells (Figure 19D), suggesting 
that sialic acid interactions may assist mCEACAM-dependent JHM S cell-cell fusion.  
From these findings, we conclude that sialic acids can enable a CoV S-mediated cell-
cell fusion process without requiring a prototypic proteinaceous receptor. 
A JHM-CoV Spike Mutation Increases mCEACAM-independent Cell Binding 
To date, analyses of the multi-RBD CoV S proteins have revealed that all 
identified sialic acid interactions exist on S protein domain As (105, 113, 125, 126), 
while most protein receptor interactions point to S protein domain Bs (103, 106, 107).  





(CEACAM) receptors (104). From these findings, and our findings that JHM S does 
interact with host sialic acids, we inferred that the JHM-CoV S domain A could contain a 
novel dual-receptor binding capability, able to bind both sialic acid and CEACAM 
receptors. If this were true, then we expected to be able to manipulate the sialic acid-
dependent JHM S phenotypes via specific domain A mutations. Sialic acid binding sites 
on beta-CoV S proteins were originally inferred from mutagenesis studies (105), and 
most recently, from structural resolution of S proteins in complex with sialosides (113, 
114).  Mutations in the inferred site did decrease sialoside binding (105, 125), even 
though they are distal from the structurally resolved sialoside binding grooves (113, 
114). Upon comparings the sialoside binding site and the distal site between MHV and 
the sialic acid-binding B-CoV domain As, we noted that, while the sialoside binding sites 
were relatively divergent, the distal sites were surprisingly conserved, based on both the 
crystalized structures and the amino acid sequences. Here we noted a single variation 
in the distal site. Among a stretch of 4 residues important for sialate-binding activity of 
B-CoV S domain A, JHM differed only at residue 176, where there is a Gly on a 
divergent loop in place of the orthologous B-CoV Glu170 (Figure 20A).   
To evaluate the importance of this divergence to sialic acid binding, we 
constructed a G176E – mutant JHM-CoV S protein. We hypothesized that this single-
residue change could enhance the mCEACAM-independent activities of JHM S. We first 
verified that G176E S protein expression, proteolytic processing, and VLP-incorporation 






Figure 20. JHM S G176E Mutation Elevates Target Cell Binding. (A) Structural 
superimposition and sequence alignment of B-CoV S domain A (PDB: 4H14, green) and 
A59 S domain A (PDB: 3JCL, magenta) using PyMOL. Side chains in stick 
representation are included for residues of interest. The sialic acid binding site is circled 
with dash line, and the distal site is boxed. (B) Western blot detection of VLP-associated 
S proteins. Particle-incorporated spike (S) proteins were detected using mouse α-MHV-
S (10G). (C) VLPs lacking S proteins, or bearing JHM (WT) or JHM (G176E) S proteins, 
were applied to HeLa cells pretreated with either vehicle or NA, at equivalent Rluc 
levels. Experimental procedures, data acquisition and processing were performed as 
described in the Figure 17 legend. 
 
Notably, when VLPs bearing no S, WT S, or G176E S were inoculated onto HeLa cells 
at equivalent Rluc multiplicities, about twice more G176E-VLPs bound to HeLa cells 





to NA pre-treatment of the cells (Figure 20C). Because a single residue mutation on 
JHM S domain A conferred a gain-of-function to cell binding, our results suggested that 
JHM S engages target cell sialic acids via its S domain A, supporting the notion that 
JHM S domain A is an evolutionary intermediate between sialic acid binding and protein 
receptor engagement. 
A JHM-CoV Spike Mutation Increases mCEACAM-independent Membrane Fusion 
 If sialic acid engagement enables JHM S mCEACAM-independent cell-cell 
fusion, then a gain-of-function mutation such as G176E should enhance this fusion 
signature. To correlate the increased cell binding of G176E mutant with membrane 
fusion, we compared the syncytial potency of JHM wild type and G176E-mutant S 
proteins. The DSP-complementation-based cell-cell fusion system was modified slightly. 
Cell-cell fusion effector cells were co-transfected with expression plasmids for DSP1-7, 
with JHM WT S, G176E S, or vector control. Target cells were co-transfected with 
plasmids for DSP8-11, with mCEACAM or vector control. Effector and target cells were 
mixed and cell-cell fusion measured by DSP 1-7 : DSP 8-11 complementation (Figure 
21A), visualized as GFP-positive syncytia via confocal fluorescent microscopy (Figure 
21B), and quantified by measuring Rluc signals (Figure 21C), where relative signals 
over background (No S) were depicted.  Of note, when mCEACAM receptors were 
present, synyctia induced by wild type and mutant S proteins developed comparably, 






Figure 21. JHM S G176E Mutation Increases mCEACAM-independent Cell-cell 
Fusion. (A) Schematic for JHM S protein-mediated cell-cell fusion measurements. GFP 
and Rluc signals arise only after S-expressing effector cells fuse with target cells, which 
enables DSP1-7:DSP8-11 complementation. (B) Live-cell images of the syncytia formed 
by S-expressing cells, without (left) or with (right) mCEACAM on target cells.  Images 
were captured by EMCCDCascade 2 camera and compiled using Imaris 8.3.1. (C) 
Quantification of syncytial developments. After imaging, cells were lysed and their Rluc 
activities quantified. Data are presented as fold-increases above background (“No S”) 
values. Statistical analyses were performed as described in the Figure 17 legend. 
 
In contrast, in the absence of mCEACAM, the G176E spikes were significantly more 





VLP cell binding capabilities (Figure 20C). We concluded that a single point mutation in 
the JHM-CoV S domain A increases the cell binding and membrane fusion activities of 
S proteins, independent of the prototype JHM protein receptor. Furthermore, our data 
supported the JHM neuropathogenesis model where JHM interneuronal spread is 
facilitate by S : sialic acid interactions. 
SECTION 3: MERS Spike Utilizes Host Sialosides During Viral Entry and Spread 
MERS-CoV Spikes Mediate Cell Fusion without Requiring hDPP4 Protein 
Receptors 
MERS-CoV S domain Bs bind to host protein (hDPP4) receptors (106, 137, 154), 
and MERS-CoV S domain As bind to host sialic acids (114, 126). While the principle 
receptor hDPP4 confers cells susceptible to MERS-CoV infections (137, 154, 161), 
recent studies have revealed some biological importance for MERS S domain A : 
sialoside interactions on viral infections. First, de-sialylation significantly reduced MERS 
pp and MERS-CoV entry into susceptible cells (114, 126). Also, antibodies against 
MERS S domain A can be neutralizing (149, 150), and protect mice from dying (151). In 
constrast, how and whether host sialosides can be utilized for MERS S-mediated cell-
cell fusion have not been explored. Our recent data suggested that weak sialic acid 
interactions can be sufficient for protein receptor-independent viral spread, which could 
be a major contributing factor to specific CoV tropism and pathogenesis. This raised the 
question of whether MERS-CoV spikes can catalyze cell fusions after the binding of 
their S domain As to cellular sialosides, and independent of high-affinity protein 





mediated cell-cell fusions between hDPP4-negative DBT cells were measured by DSP 
1-7 : DSP 8-11 complementation. Similar to the JHM S cell-cell fusion analysis in the 
previous section, effector cells expressing DSP1-7, MERS S or vector control, were 
mixed with target cells expressing DSP8-11 and various cellular factors (Figure 22A). 
Cell-cell fusions were quantified by measuring Rluc signals from DSP-
complementations, and relative signals over background (No S in effector cells and no 
exogenous factors in target cells) were depicted (Figure 22B). First, comparing to the 
No S background control, MERS S facilitated cell-cell fusion in the presence of hDPP4, 
and the Rluc signal further increased ~6-fold upon introduction of the triggering protease 
hTMPRSS2. This is in agreement with the current understanding of MERS S fusion 
being S-dependent, hDPP4-facilitated, and protease-triggered (160, 170, 238). 
Remarkably, our data suggested that syncytial development mediated by MERS-CoV S 
proteins did not require hDPP4, but did require sufficient levels of the S protein-
activating protease hTMPRSS2 (Figure 22B). Specifically, this fusion was not due to 
MERS S using hTMPRSS2 as a surrogate receptor, because the catalytically-inactive 
TMPRSS2 (S441A) did not facilitate any cell-cell fusion (Figure 22B). The MERS S-
mediated cell fusions contrasted with those generated by 229E-CoV S proteins. We 
noted that 229E S-mediated fusions absolutely required target cell hAPN protein 
receptors, whose fusion was further elevated ~50-fold with added hTMPRSS2 
proteases (Figure 22B). Interestingly, 229E S do not bind sialic acids (126), suggesting 
the observed MERS S-mediated, hDPP4-independent cell-cell fusion could be enabled 






Figure 22. MERS S Mediates Cell Fusion without Requiring hDPP4 Protein 
Receptors. (A) Schematic for MERS S protein-mediated cell-cell fusion measurements, 
where murine DBT effector cells either with or without MERS S were laid onto DBT 
target cells either with or without hDPP4 or hTMPRSS2.  (B) Effector cells expressing 
the indicated S proteins were cocultured with target cells expressing hTMPRSS2 or the 
catalytically inactive mutant hTMPRSS2 (S441A), and/or protein receptors (hDPP4 for 
MERS, and hAPN for 229E).  The dotted line represents background Rluc signals. Data 
are presented as fold-increases above background (“No S vs. Vector”) values. Data 






Thus, with sufficient cell-surface protease activities, the primary hDPP4 receptor was 
dispensable, conceivably because the secondary sialate-binding RBDs can operate at a 
stage in the process. This is the first documentation of hDPP4-independent fusion by 
MERS S proteins. 
MERS Spike-mediated, Protein Receptor-independent Membrane Fusion Depends 
on S Domain A and Host Sialosides 
To directly determine whether the observed hDPP4-independent MERS S cell-cell 
fusion is facilitated by S : sialoside interactions, secreted, soluble S domain A (S1A-Fc) 
proteins were constructed and added in titrated levels during the cell-cell fusion assays. 
Notably, exogenous domain As interfered with hDPP4-independent MERS S-mediated 
fusion in a dose-dependent manner, but had no effect on fusion when hDPP4 was 
present (Figure 23A). This result suggested that the observed fusion was facilitated by 
S domain A engagement with target cell factors. To determine whether target cell sialic 
acids are the domain ligand that operate in the cell fusion process, NA was added to 
cell-cell fusion time-course experiments (Figure 23B). Comparing to the MERS S-
mediated DBT cell-cell fusion in the absence of hDPP4 (Figure 23C), whose fusion 
signal was inhibited by exogenous NA, exogenous NA had no effect on the cell fusion 
when hDPP4 was present (Figure 23D), implying a role of host sialosides in hDPP4-
independent fusion. Taken together, these results further suggested that either of the 
two S RBDs, domain A or domain B, can tether S proteins to target cells for subsequent 






Figure 23. MERS hDPP4-independent Cell-cell Fusion Depends on Host 
Sialosides and S Domain A. (A) MERS S-expressing effector cells were mixed with 
hTMPRSS2 or hTMPRSS2/hDPP4 target cells, in the presence of a titration of soluble 
MERS-S1A-Fc proteins. Data acquisition and processing were performed as described 
in the Figure 17 legend. (B) Schematic for MERS S protein-mediated cell-cell fusion 
measurements. Rluc signals arise only after S-expressing effector cells fuse with target 
cells, which enables DSP1-7:DSP8-11 complementation. Syncytial development was 
quantified by measuring Rluc signals over time. (C and D) The kinetics of syncytial 
developments of hDPP4-negative (C) or hDPP4-positive (D) target cells, in the 
presence of the indicated NA concentrations.  Means (data points), SE (error bars), and 






An Analogous MERS-CoV Spike Mutation Similarly Increases hDPP4-independent 
Cell Binding 
We next determined whether analogous changes in S domain A of the related 
MERS-CoV also modified viral attachment. The MERS S domain A interaction with 
sialic acids has biological significance, as antibodies against S1A protects model mice 
from lethal MERS-CoV infections (151). Additionally, domain A functions may be closely 
linked to CoV zoonotic potentials. This is supported by findings that MERS S domain A 
polymorphisms exist in humans (163) and adaptive changes occur in mouse models of 
human MERS-CoV lung infection (161, 162). In mice, this selectivity was at Asn222 
(161, 162), a known glycan addition site (112, 141, 204). The specific phenotype for the 
adaptation at residue 222 has been unclear. Furthermore, evolutionary speaking, 
Asn222 is a documented hypervariable residue. Among the two most MERS-related bat 
CoVs, HKU4 and HKU5, the former group has maintained this glycosylation site while 
the same site is absent in the latter group (Figure 24A). Remarkably, upon 
superimposing the domain A structures for B-CoV, MHV, and MERS-CoV, we noted 
that the MERS Asn222 position overlaps closely with B-CoV residue Glu170 and MHV-
CoV residue Gly176, in the putative sialioside-binding distal site (Figure 24B). Due to 
this profound locational similarity, we constructed MERS VLPs to determine whether 
this S proteins with the Asn222 change impacted cell binding. Because of the weak-
interaction nature between MERS S and sialosides, the VLP system was adapted to 
make MERS S-bearing particles where the S proteins are oligomerized similar to 






Figure 24. MERS S N222 is a Hypervariable Residue within the Sialoside-binding 
Distal Site. (A) Comparison of selected MERS S sequences relative to bat MERS-like 
HKU4 and HKU5. MERS S residue N222, as well as hDPP4-binding loops 1 and 2, are 
delineated by red boxes. MERS S1 structure is from PDB: 5X59. (B) Structural 
superimposition of B-CoV S domain A (PDB: 4H14, green), A59 S domain A (PDB: 
3JCL, magenta), and MERS S domain A (PDB: 5X4R, yellow) using PyMOL. MERS 
S1A residue N222 (stick representation) is located proximally to B-CoV S1A residue 






To test this, we produced MERS-CoV VLPs and evaluated their sialate binding 
properties. Comparing to spike-less (No S) MERS VLPs, S-bearing VLPs, when 
inoculated at equivalent Rluc multiplicities, enabled agglutination of human erythrocytes, 
and this agglutination was eliminated via NA pre-treatment of erythrocytes (Figure 25). 
This result implied that the MERS VLPs did incorporate and display S proteins the same 
way as authentic viruses, which enabled detectable sialoside-binding activities. We then 
constructed wild type (WT) and N222D VLPs containing internal Rluc. We then verified 
that WT and mutant S proteins were processed and incorporated comparably (Figure 
26A). 
 
Figure 25. MERS-CoV VLPs Resemble Authentic Viruses. (A) The indicated IAV pps 
or MERS VLPs were placed into V-bottom wells and incubated for 1 h at room 
temperature.  The VLPs (No S or MERS S) were present at equivalent levels, as 
measured by their internal Rluc contents.  Pre-warmed (37°C) human adult 
erythrocytes, either with or without prior NA treatment, were added to a final 0.25% v/v. 
Hemagglutination was scored after 2 to 12 h at room temperature. The experiment was 
performed two times. (B) MERS VLPs (No S or MERS S) were serially 2-fold diluted, 
placed into V-bottom wells, and incubated for 1 h at room temperature.  Pre-warmed 
(37°C) human adult erythrocytes were added to a final 0.25% v/v. Hemagglutination 
was scored after 2 to 12 h at room temperature. The experiment was performed two 





After normalizing particle input of VLP bearing no S, WT S, and N222D S based on their 
internal Rluc signals (Figure 26B), VLPs were inoculated onto various target cells, and 
binding was assessed by quantifying cell-associated Rluc. Intriguingly, we saw the 
effect of G176E mutation on JHM S mirrored by N222D mutation on MERS S. First, 
N222D did not alter VLP binding to permissive human lung derived Calu3 cells. This 
was in stark contrast to the VLP binding signatures for the non-permissive mouse lung 
derived LET-1 and mouse brain derived DBT cells, whereas WT S mediated very 
modest levels of VLP binding, N222D S elevated that binding dramatically (Figure 26C). 
While the involvement of MERS S domain A in VLP binding to Calu3 cells was difficult 
to assess, mainly due to the fact that these human cells express hDPP4 protein 
receptor for MERS-CoV, the mouse-adaptive mutation at Asn222 clearly enhanced the 
ability of S domain A to bind to murine cells (Figure 26C). 
An Analogous MERS-CoV Spike Mutation Similarly Increases hDPP4-independent 
Membrane Fusion 
Since we had observed remarkable similarities on the effect of mutations in the 
sialoside-binding distal site on viral binding for both JHM and MERS S proteins, we next 
considered whether this MERS-CoV adaptation for increased cell binding had 
consequences in MERS S – mediated cell-cell membrane fusion, similar to the JHM-
CoV G176E mutant. To this end, cell-cell fusion assays were set up to observe the 
effect of N222D change either in the presence or absence of the hDPP4 protein 






Figure 26. MERS S N222D Elevates Target Cell Binding. (A) Western blot detection 
of MERS WT and N222D S proteins in VLPs. Particle-incorporated spike (S) proteins 
were detected using mouse α-C9. (B) Bald (No S), WT or N222D S-bearing VLPs 
contained equal internal Rluc activities. (C) VLPs were added at equivalent Rluc input 
multiplicities to human Calu3, murine LET-1 cells, and murine DBT cells.  After 2h at 
4°C, cell-associated Rluc activities were quantified, and data were presented after 
subtracting background (“No S”) Rluc+ VLP levels. Data acquisition and processing 
were performed as described in the Figure 17 legend. 
 
Again mirroring the effects we saw for JHM S, we found that the N222D adaptive 
mutant S proteins did indeed exhibit enhanced cell fusion, relative to wild type S 
proteins (Figure 27A), but this was only observed by eliminating hDPP4 (Figure 27A, 
left), which removes the dominant domain B : protein receptor interaction and demands 





and cell fusion, specifically to verify whether the adaptive effects of N222D is indeed at 
the level of domain A : host engagement, we determined whether soluble N222D 
domain A (N222D S1A-Fc) proteins would suppress cell fusion more effectively than 
soluble WT domain A (WT S1A-Fc) proteins. We therefore constructed N222D S1A-Fc 
and added it at equivalent molar ratios with WT S1A-Fc into the cell-cell fusion assay 
(Figure 27B). Soluble mCEACAM (mCEACAM-Fc) proteins were added as the negative 
control. Indeed we found that exogenously added N222D S1A-Fc proteins suppressed 
hDPP4-independent cell-cell fusions more potently than the corresponding WT S1A-Fc 
(Figure 27C), further reinforcing the direct relationship between domain A binding to 
cells and resultant cell-cell fusion and the adaptive benefits of N222D. Altogether, these 
findings support the hypothesis that MERS-CoV and JHM-CoV can acquire increased 
cell binding through S protein domain A mutations, which consequently allow for more 
robust cell-cell fusion capability.  Both of these CoVs can procure these cell binding and 
cell fusion properties through similarly-localized S1A mutations, suggesting a common 






Figure 27. MERS S N222D Increases hDPP4-independent Cell-cell Fusion. (A) 
Effector cells expressing the indicated S proteins were cocultured with target cells 
expressing hTMPRSS2 and/or hDPP4. (B) Western blot detection of various purified Fc-
tagged proteins. Protein concentration was assessed using Nanodrop (Thermo Fisher), 
and hIgG1 (Sigma) was loaded as a quantification control. (C) MERS S-expressing 
effector cells were mixed with hTMPRSS2-expressing target cells, in the presence of 
the indicated Fc proteins.  All Fc proteins were at 10 uM concentration throughout the 
coculture period. Data acquisition and processing were performed as described in the 






Summary of Data 
The central goal of our study was to identify and characterize specific ways CoVs 
utilize their S proteins during viral entry and spread. Our methodology was to develop 
and utilize reductionist approaches where different steps and individual factors can be 
assessed in isolation. Our results indicate that CoVs that have developed high-affinity 
interactions with protein receptors can nonetheless utilize weak interactions with host 
sialic acids to assist in the establishment of de novo CoV infections, as well as 
spreading existing ones. Interestingly, sialic acid interactions contribute to different 
stages of S-mediated membrane fusion in viral entry than in viral spread. Remarkably, 
CoVs readily fine tune these interactions to adapt to specific biological niches. 
First, we sought to identify the requirements for CoV S-mediated membrane 
fusion, in the context of viral particles. Using an in vitro fusion detection system, we 
determined the minimum requirements for CoV viral particle fusion to be the CoV S 
protein, its protein receptor, and a triggering protease. This conclusion was drawn from 
the direct detection of membrane fusion events in the absence of live cells (Figure 9B), 
hence this system is devoid of other complex cellular factors, as well as the constant 
replenishment of these factors. In this system, we observed the role of hDPP4 to be 




in this context, the presence of exogenous protease was sufficient to trigger membrane 
fusion (Figure 14A and C). To our knowledge, this is the first characterization of MERS-
CoV S-mediated membrane fusion in a cell-free context, and the second for CoV entry 
in general (239). 
Next, we identified MHV-JHM elicits sialic acid interactions. To narrow the viral 
binding agent of sialic acid, we developed an MHV VLP system and identified the 
binding agent to be the JHM S protein. We demonstrated for the first time that sialic acid 
interactions are responsible for most of the JHM viral attachment to target cells (Figure 
17D), whereas its protein receptor mCEACAM is specifically required for viral entry 
(Figure 18B). Sialic acid interactions were subsequently identified to assist JHM-CoV 
mCEACAM-dependent entry (Figure 18C). We also found that sialic acid is the cryptic 
receptor JHM S engages to mediate mCEACAM-independent cell-cell spread of 
infections into cells of various animal species (Figure 19C), a widely-recognized feat 
whose mechanism had been elusive until now. 
We further identified a point mutation in JHM S domain A that specifically 
elevates the S-mediated, mCEACAM-independent, viral binding (Figure 20C), as well 
as enhancing mCEACAM-independent cell-cell fusion. The correlation of these findings 
suggest that, in addition to its mCEACAM engagement, JHM S protein domain A also 
engages host sialic acids. The dual-valent JHM S domain A therefore potentially 
qualifies as an evolutionary intermediate representing a switch between sugar-binding 




Energized by our findings on the mechanism of JHM S-mediated mCEACAM-
independent cell-cell fusion, we were the first to observe an analogous, hDPP4-
independent cell-cell fusion mediated by MERS S proteins, in the presence of sufficient 
levels of target cell surface proteases (Figure 22B). Similar to JHM S, the alternative 
receptor MERS S utilized to mediate this fusion is likely sialic acids, because (1) this 
fusion was not elicited by the sialic acid-insensitive 229E-CoV S (Figure 22B); (2) the 
fusion depended on the binding activity of the sialic acid-binding S domain A (Figure 
23A); (3) the fusion was reduced by the introduction of NA (Figure 23C). 
Finally, because residue 222 of MERS S domain A is a hyper-variable region 
(Figure 24A), and is under the selective pressure during viral zoonosis (161–163), we 
decided to characterize its adaptive effects. We first noted that the structural position of 
residue 222 overlaps with the gain-of-function mutation we identified in JHM S (Figure 
24B). Remarkably, a change in the 222 position functionally resonated our observations 
for JHM S, where the mutant enhance viral attachment to target cells (Figure 26C), as 
well as elevated MERS S fusion capabilities against the hDPP4-negative DBT cells 
(Figure 27A). These results are the first to identify functional advantages between wild 
type and adapted MERS S domain As, and they suggest that fine-tuning weak sialic 
acid interactions is an integral element for the zoonotic potential of MERS-CoV. 
Overall, these results indicate that CoV S proteins utilize host factors in ways 
more extensive and intricate than previously appreciated. The same host factor can be 
differentially utilized during viral entry and spread. Weak interactions, which are difficult 




CoVs readily evolve modification to these modest interactions to adapt to new biological 
niches. 
In Vitro Particle Fusion Identifies Minimal Fusion Requirements 
 Fluorescence have been used to analyze CoV membrane fusion events (239). 
Here, we used FRET induction as a direct readout for membrane fusion. In our in vitro 
fusion system, the interior of one particle is labeled with a fluorescent donor (GFP) and 
another an acceptor (mCherry). Because the particle interiors are separated by two lipid 
bilayers and their associated membrane proteins (e.g. S, hDPP4; Figure 9B), only 
through membrane fusion can the two fluorescent proteins be in close enough proximity 
for FRET (Figure 13A). It has been previously demonstrated that MERS-CoV entry is 
spike-directed, receptor-facilitated, and protease-triggered (Figure 8B, and reviewed in 
(160)). However, because traditional studies used live cells as viral entry targets, it has 
been difficult to assess the sufficiency of these entry factors in mediating MERS-CoV 
entry. The in vitro particle fusion system we developed avoids some major limitations of 
using live cells to analyze entry factors. First, cells maintain complex biological 
processes, involving a large number of factors that are generally difficult to assess in 
isolation from one another. This may leading to incorrect interpretations of factors for 
viral entry. Porcine epidemic diarrhea virus (PEDV) allegedly uses APN as its protein 
receptor (240), but studies ten years later have demonstrated that APN is not a 
functional receptor for PEDV, but rather, its enzymatic activity promotes PEDV viral 
infection (241, 242). Another familiar scenario is that the viral entry characteristics 




generally resulted from differences in the quantity and/or the quality of the various entry 
factors in different cell types. The particles in our in vitro fusion assay have greatly-
reduced levels of complexity in terms of unaccounted cell factors. Additionally, these 
particles are biologically dead, in that they contain no live signaling pathways that may 
complicate the viral fusion process. Hence, when factors are characterized in this 
reductionistic approach, they are very likely to operate independently from other cellular 
processes, at least in the context of S-mediated viral fusion. Taken together, our data 
suggest that, to fuse a viral envelope with a target membrane, MERS S requires only 
hDPP4 engagement and proteolytic processing. 
 We have noted a particular limitation of the in vitro fusion system. MERS S has 
been observed to associate with host sialic acid species (126). This association, albeit 
weak, is responsible for the initial cell attachment step prior to viral entry (114, 126). 
Since we did not detect any particle co-localizations between S-bearing pps and Bald 
pps (Figure 11B, S x Bald), our system does not appear to facilitate efficient MERS S : 
sialic acid interactions. This may be explained by the differences in the three-
dimensional structures between a viral envelope and the cell plasma membrane. When 
a virus lands on a cell, its MERS S proteins are able to interact with the various sialic 
acid moieties on the relatively-flat plasma membrane. Overtime, what lacks in the 
MERS S : sialic acid binding strength can be made up in quantity. Indeed, avidity is 
required for efficient MERS S – sialic acid interactions (126). On the contrary, when two 
virions interact, the contact zone is very limited. Together with a finite quantity of sialic 




do see IAV HA-bearing pps co-localizing with Bald pps (Figure 11B, IAV HA x Bald), 
mirroring a previously documented comparison (126). Therefore, the in vitro fusion 
system may yet be sufficient to characterize viral glycoprotein : sialic acid-mediated 
membrane fusions, if this interaction is of high affinity. An alternative interpretation of 
this apparent limitation to detect sialic acid binding could be simply that sialic acids were 
not overexpressed, and hence this in vitro fusion system requires the enrichment of 
entry factors onto the HIVpp envelope. 
JHM Spike Utilizes Host Sialosides for Viral Attachment 
Viruses frequently begin infection by attaching to cellular sialic acids (243). Such 
viruses include several CoVs, which attach to sialates via S domain As (99, 100), at low 
affinity (113), but relatively high multivalent avidity (125, 126).  Atomic resolution 
structures of 9-O-acetylated sialic acid in complex with the human OC43-CoV domain A 
(113) as well as several sialosides in complex with the MERS-CoV domain A (114) have 
revealed architectures of CoV-sialate binding sites. Yet even with this detailed 
understanding, it is not clear whether sialic acids confer susceptibility to CoV infection 
on their own, or whether proteinaceous CoV receptors are also required.  In considering 
this question, we first focused on the murine MHV JHM-CoV strain.  This strain can 
infect cells and mice that lack the proteinaceous MHV receptor, mCEACAM1a (129, 
143, 188, 196, 197, 200, 224, 225). This strain is also unusually sensitive to proteolytic 
activation of spike-mediated membrane fusion (173), and therefore, we hypothesized 
that a low-affinity cell binding event, conceivably to cellular sialoglycans, might be 




We found that JHM-CoV binding to cells depended on host sialic acids. This 
binding accounted for initial virus attachment to cells (Figure 17D), which facilitated 
subsequent virus engagement with proteinaceous CEACAM receptors (Figure 18B and 
C). The identification of this interaction was most likely achieved by the VLP system. 
Traditionally, soluble RBDs are made to assess their interactions to various cellular 
factors. This enables any phenotype to be attributed to that specific RBD. Soluble MHV 
S domain A proteins have been routinely used in this context as the negative control for 
sialic acid interations (125). Recently, the S domain A of MERS-CoV and HKU1-CoV 
have been demonstrated to bind sialic acids, but this binding was only detected when 
the soluble domains were oligomerized onto nanoparticles at a density comparable to 
authentic viruses (125, 126), implying that weak sialic acid interactions with CoV spike 
depends on avidity, not affinity. We therefore deployed a VLP system to identify and 
characterize the putative weak JHM S : sialoside interactions. We verified that JHM S 
proteins are assembled on VLPs similar to authentic viruses (Figure 16B). We decided 
to use VLPs over viruses for another advantage they offer. Traditionally, to characterize 
viral particle binding to host cells, cells were extensively rinsed to remove unbound 
particles, which minimizes background signals. We reasoned that these rinses likely 
also remove weakly-associated viral particles, and end up retaining only strong binders. 
By using spike-less (No S) VLPs as the negative control, we theoretically can control for 
all background binding that is not contributed by the S protein, and therefore minimizes 
the need for rinsing. These advantages together may have enabled the detection of 




be widely-adapted to assess previously underappreciated modest, but nonetheless 
biologically meaningful, interactions between CoVs and their hosts. 
Differential Host Sialoside Utilizations for Viral Attachment and Cell-Cell Fusion 
Later in the infection cycle, JHM-CoV spikes facilitated cell fusions and further 
virus dissemination in a sialic acid – dependent manner (Figure 19C). MERS-CoV spike 
proteins could similarly fuse cells together without requiring prototype protein (hDPP4) 
receptors, presumably by utilizing sialoside receptors to engage neighboring cells 
(Figure 23C). These findings, summarized in figure 28, suggest that CoV-cell entry and 
intercellular spread involves the lectin-like activities of spike proteins during both virus-
cell attachment and infected-cell expansion into syncytia. 
 
Figure 28. Sialic Acid and Protein Receptor Binding Events During CoV Infection. 
In entry, CoV S proteins mediate weak interactions with abundant host surface sialates, 
keeping viruses concentrated on cells yet potentially diffusible across plasma 
membranes. S proteins subsequently engage protein receptors and are proteolytically 
activated into membrane fusion-inducing conformations. In spread, canonical virus 
release is concomitant with cell-cell fusion. Cell-cell fusion involves S binding to sialic 
acids, and does not require protein receptors, allowing infection to spread beyond the 




While sialic acids affected virus-cell binding (Figure 17D), infection by JHM-CoV 
(Figure 18C) and cell entry by JHM-CoV VLPs (Figure 18B), on the other hand, required 
the proteinaceous mCEACAM receptors. This suggests that, prior to protein receptor 
engagement, CoV binding to target cells may be a physiologically separate step, 
requiring unique cellular factors. Therefore, one possibility is that multivalent CoV-
sialate interactions are not sufficient to hold viruses throughout a virus particle-cell 
membrane fusion process, and that sialic acids may instead only tether viruses, 
transiently, onto host-cell surfaces, as they diffuse quasi-two-dimensionally along the 
target cell plasma membrane. Hence, this locally-elevated viral concentration at or near 
the plasma membrane may promote the likelihood CoVs can assume more stable 
interactions with high-affinity protein receptors. Yet, while insufficient for de novo viral 
entry, sialic acid binding may advance the spike-mediated cell-cell membrane fusions 
that are observed in several CoV infection processes (187, 189, 191, 196). This is likely 
due to the intrinsic differences between the fusion entities. In cell-cell fusion, the plasma 
membrane of the infected cell is juxtaposed against the plasm membrane of 
neighboring uninfected cells. Therefore, spikes on infected-cell surfaces are steadily 
directed at uninfected (target) cells in close proximity. In this scenario, there is no 
functional equivalence to viral attachment, since these cells are not liable to diffuse 
away as would cell-bound viruses. However, even though close, the spike proteins on 
the infected cell membrane may not be close enough to be processed by target cell 
surface proteases. Therefore, even a modest interaction with the target cell, which could 




effective range of surface proteases, which triggers membrane fusion. In this way, CoV 
cell-cell fusion still may require attachment to target cell sialates in order to effect 
membrane fusion. In support of this contention, we found correlations between sialic 
acid abundance and membrane fusion activity (Figure 19C and Figure 23C).  This was 
observed for both JHM- and MERS-CoV spikes, and notably, both the JHM- and MERS-
CoV spike-directed cell fusions took place independent of any proteinaceous receptors. 
These correlations suggest that sialic acids on uninfected cells can arrange spikes such 
that they will then operate cooperatively to pull opposing plasma membranes into 
coalescence. 
Host Surface Protease Utilization and CoV Pathogenesis 
 Traditionally, the determination of proteolysis being an entry requirement for 
CoVs have been assessed by adding various exogenous soluble proteases (e.g. 
trypsin, furin, and cathepsins) during the entry process (Figure 11A and 12, and 
reviewed in (170)). While effective, this approach has led to inaccurate interpretations 
on CoV protease preferences, particularly overlooking the importance of type II 
transmembrane serine proteases (TTSPs). In recent years, utilizing specific small 
molecule inhibitors and targeted overexpression, these cell surface proteases have 
been revealed to be preferentially utilized by many CoVs (138, 167, 173, 182, 194, 
212). To date, the roles of TTSPs have been well characterized to facilitate facile CoV 
entry kinetics (138, 161, 174, 182). We have identified a new role for TTSP late in the 
CoV viral lifecycle. We observed for the first time that MERS S mediates hDPP4-




level of the surface protease hTMPRSS2 (Figure 22B). Because hTMPRSS2 is highly 
expressed on type II pneumocytes and resident alveolar macrophages in the human 
lower respiratory tract, the physiological site of MERS-CoV pathogenesis (244), our 
observation hence suggests that established MERS-CoV infections can be readily 
spread into neighboring cells, skipping de novo viral assembly, even if the neighboring 
cells have low hDPP4 expression levels. This facile spread of infection may contribute 
to MERS-CoV reaching high enough viral replication to delay the onset of IFN response, 
the main cause of MERS-induced pneumonia and death (66). Additionally, this 
protease-dependent facile cell-to-cell spread may be an evolutionarily-conserved CoV 
strategy, since it has been demonstrated that exogenous trypsin is required for 
successful syncytia-dependent propagations of bat MERS-like CoVs, PDF2180-CoV 
and HKU5 (245). Interestingly, while SARS-CoV has reduced sensitivity to TTSPs, the 
closely-related, pandemic-ongoing, 2019-nCoV sequence suggested elevated 
sensitivity to TTSPs. It would be enlightening to assess whether SARS-CoV-2 has 
gained the ability to spread into hTMPRSS2+ hACE2- target cells. 
The Evolution of CoV S Protein Domain A 
This differential utilization of sialoside and protein receptors raises questions 
about CoV evolution. The CoV S domain As fold into a galectin-like structure (104, 105, 
108, 109, 112, 113, 116) and several domain As demonstrably bind carbohydrate 
ligands (113, 114, 125, 126). The domain As of MHVs, however, appear to be the 
exception where, prior to this report, they were considered to bind only protein 




by MHV domain As, Li et al (105) proposed that ancestral MHV-CoVs bound 
carbohydrates, with adaptive evolution generating the present-day CEACAM-binding 
sites. This proposal infers the existence, past or present, of evolutionary intermediates 
capable of binding both mCEACAM and sialic acid (Figure 4C). Contrary to previous 
generalizations, we have observed sialic acid binding activities on MHV-JHM S proteins 
(Figure 17C). Using targeted mutagenesis, this sialic acid interaction was attributed to 
JHM S protein domain A (Figure 20). Hence, based on our findings, the MHV JHM-CoV 
strain meets the criteria for such an intermediate – a virus in which its S domain A 
retains two “receptor” binding activities, one for carbohydrate and the other for protein. 
Interestingly, the mCEACAM-binding motif on JHM S domain A is close and may be 
partially overlapping with its putative sialic acid binding pocket, based on studies of 
related, known sialic acid-binding domain As (104, 113, 114). Therefore, conceivably 
these two receptor capabilities interact, such that increased affinity for one ligand 
reduces affinity for the other. Mutants with relatively high affinity for sialic acid may bind 
poorly to mCEACAM, while strains lacking sialic acid binding may demonstrate strong 
mCEACAM affinity. An inverse relationship would be consistent with Li et al., who 
proposed that acquisition of a CEACAM binding site concomitantly destroyed a sialate 
site (105). And by extension, these ligand affinity “trade-offs” would result in CoV 
tropism changes. In support of this, while both the liver-tropic MHV-A59 and the neural-
tropic MHV-JHM engage protein mCEACAM receptors, JHM differs in a few positions 
among all the residues facilitating mCEACAM binding as determined by the A59 domain 




The Co-Evolutionary Relationship between CoV S Protein and HE 
Yet perhaps more intriguing relationships are between CoV S and hemagglutinin-
esterase (HE) proteins, a second, smaller viral glycoprotein that is expressed by some 
beta-CoVs. While both S and HE bind sialosides (246, 247), HE possesses additional 
esterase activity (228, 229). Often, the expression of HE correlates with the ability of 
CoV S proteins to bind to host sialic acids. The S proteins of BCoV, OC43-CoV, and 
HKU1-CoV all recognize 9-O-acetylated sialic acids (113, 125), and these CoVs also 
incorporate HEs that recognize the same sialic acid species (246). Esterase activities 
within HE proteins de-acetylate sialosides, and it has been documented, in HKU1-CoV 
infections, that HE activity destroys an S-specific sialoside receptor, keeping viruses 
detached from cells and allowing for virus dissemination (228), a relationship analogous 
to IAV HA and NA (248). Several MHV strains including JHM express a viral HE, which 
binds and deacetylates 4-O-acetyl sialiate (229).  Similar to HKU-1-CoV HE, MHV HE 
could destroy MHV sialoside receptors and facilitate dissemination. In our study, MHV 
strain A59 did not bind sialic acids, which correlated well with it not retaining an intact 
HE open reading frame (226, 227). Conversely, we determined that MHV strain JHM did 
bind sialic acids and this coincided with its expression of HE. These observations 
collectively suggest that the presence of HE correlates with the viral reliance on host 
sialic acids, specifically, S : sialic acid – mediated CoV entry processes. For MHVs, their 
abilities to utilize sialic acids may be the determinant for their tropisms. Indeed, MHV-




elevated neurovirulence (249). Our identification of the JHM S : sialic acid interaction is 
in agreement with these views. 
While the expression of HE generally implies S : sialic acid interactions, CoV S 
may develop modest sialic acid interactions in the absence of HE expression. MERS-
CoV genome does not encode HE, but its S protein does bind sialic acids, albeit weakly 
(126). While evolutionary selection does impose on MERS S domain A (161–163), and 
we were first to observe that this selection resulted in enhanced viral binding (Figure 
26C), the increases in MERS S : sialic acid affinity for sialates may be limited by the 
absence of a MERS-CoV HE gene. Conversely, for reasons yet to be determined, CoVs 
adapted to human airways may not benefit from proficient acetyl-removing activities, as 
demonstrated in OC43-CoV and HKU1-CoV, whose HE proteins are going through 
progressive losses in their lectin and esterase properties (246). 
The Mechanism of the S Protein Domain A Gain-of-Function Mutations 
This study revealed S protein mutations that may endow CoVs with expanded 
tropisms, beyond that determined by prototype proteinaceous CoV receptors. The JHM-
CoV mutation, G176E, engineered to reflect sialate-utilizing BCoV (Figure 20A), 
increased viral S protein binding to cells (Figure 20C), as well as S protein-mediated 
membrane fusion (Figure 23C), independent of mCEACAM. The MERS-CoV mutation, 
N222D, an adaptation for virus growth in mouse lungs (161), operated remarkably 
similar to the JHM-CoV G176E change, with mutant S proteins showing increased 
hDPP4-independent cell binding (Figure 26C) and cell fusion (Figure 27A). The 




may enhance MERS S binding to its native sialoside moieties, but VLPs bearing the 
mutant S did not change in their binding to human lung-derived Calu3 cells, suggesting 
the mutation did not affect human sialoside binding. A potential caveat to this 
interpretation is that Calu3 cells express hDPP4, hence this condition was not a pure 
assessment of protein receptor-independent binding (Figure 26C, Calu3), even though 
our JHM results suggest that the protein receptor does not account for most of the viral 
binding to target cells (Figure 17D). Conversely, N222D may enhance the association 
between MERS S and mouse-specific sialosides, reflecting mouse adaptation. In 
support of this, the mutant S significantly elevated VLP binding to cells derived from 
both the mouse lung and brain (Figure 26C, LET-1 and DBT). It would be enlightening 
to determine whether the mutant has changed the S : sialic acid specificity, as it was 
documented that minor changes are sufficient to shift sialic acid specificity in HE 
proteins (229). In general, our findings fit with the hypothesis that viruses with these 
mutations enhanced S protein binding to certain cellular sialotopes. 
However, it is clear that the mutations characterized in this study (JHM G176E 
and MERS N222D) are not present in structurally-identified sialoside binding sites (113, 
114), but rather in the sialic acid-binding distal site. This raises alternative hypotheses to 
the mutant-induced elevation in cell attachment, including mutation-induced allosteric 
restructuring of sialoside binding sites. Allosteric remodeling has been demonstrated in 
BCoV, OC43-CoV, and porcine hemagglutinating encephalomyelitis virus (PHEV) as 
the putative role for the residues in this site (125). Alternatively, these mutations may 




as presumed binding sites for orthologous CEACAMs on MHV S proteins (250), or sites 
for CEACAM5 (251) or GRP78 (252) on MERS-CoV S proteins. 
Pathogenesis of Sialoside-utilizing CoVs 
Furthermore, this report illuminates understanding of CoV pathogenesis.  
Amongst the CoVs, the JHM-CoV strain is known for causing lethal brain infection, even 
in mice that lack the principal MHV receptor, CEACAM1a (129). JHM spike was 
identified to be the major contributor to this phenotype (129), and JHM-CoV, but not the 
related A59-CoV, spread inter-neuronally both in vivo and within in vitro cultures of 
CNS-derived cells (198, 199). Notably, neural cell membranes are known for their 
abundant sialic acid content (131). These findings, combined with evidence that cell-to-
cell syncytial spread correlates with pathogenesis in several infection models (129, 188, 
200–203), prompts a hypothesis that JHM-CoV sialic acid binding potential accounts for 
an inter-neuronal syncytial spread that is rapidly lethal.  A prediction is that variants of 
JHM-CoV exhibiting enhanced sialic acid affinity will have unusually high 
neurovirulence.  Similarly, the MERS-CoV strain causes lethal pneumonia and here it is 
significant that antibodies specific for the MERS-CoV S domain A both neutralize the 
virus and reduce infection and pathogenesis in a mouse MERS-CoV model system 
(149, 151, 204).  Conceivably, these antibodies interfere with sialic acid binding, 
reducing expansion of MERS-CoV that may take place via cell-cell fusion. Variants of 
MERS-CoV with enhanced cell-binding may be useful in assessing the in vivo 





CoV S Protein Domain A and Zoonosis 
Traditionally, studies on CoV cross-species transmissions focus on the role of the 
primary receptors and their corresponding CoV RBDs. MHV can infect non-murine cells 
by adapting its S domain A to engage the orthologous CEACAM proteins on these cells 
(250). SARS-CoV has been theorized to acquire specific S domain B modifications to 
efficiently engage human ACE2 after its zoonotic jump from civets to human (152). 
MERS-CoV has been widely-accepted to have evolved from an ancestral bat virus that 
had adapted its S domain B to engage bat DPP4 receptors (52, 253). These compelling 
observations helped promote the notion that, for CoVs that utilize a primary protein 
receptor, their utilization of orthologous forms of this receptor in other animal species is 
the zoonotic barrier. Recent studies on MERS-CoV, however, have started to challenge 
this dogma. First, the 2015 MERS-CoV outbreak in South Korean has resulted in 
human-adapted variants whose adaptive mutations actually reduced the affinity 
between S domain B and hDPP4, debunking the previous belief of a linear association 
between ortholog receptor affinity and viral transmissibility and fitness (254, 255). 
Second, upon artificially adapting MERS-CoV to humanized-mouse, S domain A 
adaptations on the same residue were identified for two independently-developed 
systems (161, 162). Concurrently, MERS S domain A was identified to engage specific 
sialosides for host attachment (126). Together, these observations argue that, in 
addition to DPP4 orthologs, host sialic acid species are also functional zoonotic barriers, 
and MERS-CoV may need to overcome both to achieve zoonosis. This understanding 




CoV and other (horses, pigs, rabbits, sheep) not, while all express appropriate DPP4 
orthologs, which can elicit susceptibility in vitro (160). In support of this, we observed 
that adaptive S domain A changes enhance viral attachment (Figure 26C), directly 
highlighting a role host sialosides can serve as a promoter of efficient cross-species 
transmissions. 
Our study also revealed a grossly underappreciated role for host sialoside 
utilization by CoVs. MHV-JHM has a profound zoonotic potential, best characterized as 
its ability to cause syncytia of cells from various animal origins that lack mCEACAM. We 
identified its underlying mechanism to be S domain A : sialic acid engagement (Figure 
19C). Surprisingly, we observed the same mechanism enabling MERS S to induce the 
analogous hDPP4-independent syncytia formation (Figure 22 and 23). Together these 
observations suggest that host sialoside-induced direct cell-to-cell spread of existing 
infections may be a general strategy CoVs utilize to boost their zoonotic potential, 
especially during early stages, when the virus has yet to develop optimal receptor 
recognitions. In light of the current severe SARS-CoV-2 outbreak in China, we analyzed 
its S sequence and found that, comparing to the closely-related pathogen of the 2002 
outbreak, SARS-CoV, SARS-CoV-2 is divergent in both the putative sialoside-binding 
site and the distal site on their S domain As (54). It is therefore likely that, compared to 
SARS-CoV, SARS-CoV-2 has acquired a more potent viral attachment to human lungs, 
as well as an elevated efficiency of hACE2-independent cell-to-cell spread. This 
prediction is in line with the epidemiological characterization of SARS-CoV-2 having a 




SARS-CoV-2 S domain A functionality would greatly advance our understanding of 
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